SG43125A1
(en)
*
|
1993-10-27 |
1997-10-17 |
Molex Inc |
Shunted electrical connector
|
US5641870A
(en)
*
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
US20040121415A1
(en)
*
|
1996-12-10 |
2004-06-24 |
King David John |
Monovalent antibody fragments
|
US8088386B2
(en)
|
1998-03-20 |
2012-01-03 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
EP1308455B9
(de)
*
|
1998-05-06 |
2006-06-14 |
Genentech, Inc. |
Anti-HER2 Antikörperzusammensetzung
|
AU2003200709B2
(en)
*
|
1998-05-06 |
2006-06-29 |
Genentech, Inc. |
Protein purification
|
ES2261589T3
(es)
*
|
1998-05-06 |
2006-11-16 |
Genentech, Inc. |
Composicion de anticuerpos anti-her2.
|
JP4780633B2
(ja)
|
1999-06-25 |
2011-09-28 |
イムノゲン インコーポレーティッド |
抗−ErbB抗体−メイタンシノイド複合体を用いた治療方法
|
CN101518653B
(zh)
|
1999-06-25 |
2015-08-19 |
基因技术股份有限公司 |
使用抗ErbB抗体-类美坦素偶联物的治疗方法
|
JP2001066308A
(ja)
*
|
1999-07-29 |
2001-03-16 |
Gsf Forschungszentrum Fuer Umwelt & Gesundheit Gmbh |
IgG抗体の不可逆的損傷の検出
|
US7414170B2
(en)
*
|
1999-11-19 |
2008-08-19 |
Kirin Beer Kabushiki Kaisha |
Transgenic bovines capable of human antibody production
|
US7074983B2
(en)
|
1999-11-19 |
2006-07-11 |
Kirin Beer Kabushiki Kaisha |
Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
|
US7820878B2
(en)
*
|
1999-11-19 |
2010-10-26 |
Kyowa Hakko Kirin Co., Ltd. |
Production of ungulates, preferably bovines that produce human immunoglobulins
|
AU1777301A
(en)
*
|
1999-11-19 |
2001-05-30 |
Hematech, Llc |
Production of ungulates, preferably bovines that produce human immunoglobulins
|
EP1260518A4
(de)
*
|
2000-03-02 |
2004-12-08 |
Kyowa Hakko Kogyo Kk |
Verfahren zur trennung und reinigung von protein
|
US20030023043A1
(en)
*
|
2000-03-02 |
2003-01-30 |
Kazuhisa Uchida |
Method of separating and purifying protein
|
CN101289511A
(zh)
|
2000-04-11 |
2008-10-22 |
杰南技术公司 |
多价抗体及其应用
|
AU2001268363B2
(en)
|
2000-06-20 |
2006-08-17 |
Biogen Idec Inc. |
Treatment of B cell associated diseases
|
US6984522B2
(en)
*
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
JPWO2002030954A1
(ja)
*
|
2000-10-06 |
2004-02-19 |
協和醗酵工業株式会社 |
抗体を精製する方法
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
EP1324776B2
(de)
|
2000-10-12 |
2018-03-21 |
Genentech, Inc. |
Niederviskose konzentrierte proteinformulierungen
|
US6979556B2
(en)
*
|
2000-12-14 |
2005-12-27 |
Genentech, Inc. |
Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
PT2000545E
(pt)
|
2001-06-20 |
2011-12-21 |
Genentech Inc |
Composições e métodos para o diagnóstico e tratamento do tumor pulmonar
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
CA2454731C
(en)
|
2001-08-27 |
2010-11-02 |
Genentech, Inc. |
A system for antibody expression and assembly
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
NZ573831A
(en)
|
2001-09-18 |
2010-07-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
CA2471431A1
(en)
|
2002-01-02 |
2003-07-17 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
EP1501856B1
(de)
|
2002-04-10 |
2012-12-19 |
Genentech, Inc. |
Anti-her2-antikörpervarianten
|
NZ535925A
(en)
|
2002-04-16 |
2008-06-30 |
Genentech Inc |
An isolated antibody that binds to a particular polypeptide
|
WO2003102595A1
(en)
*
|
2002-05-31 |
2003-12-11 |
Genetype Pty Ltd |
Maternal antibodies as fetal cell markers to identify and enrich fetal cells from maternal blood
|
EP2305710A3
(de)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetische Antikörperphagenbibliotheken
|
ES2376165T3
(es)
|
2002-07-15 |
2012-03-09 |
F. Hoffmann-La Roche Ag |
Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4.
|
EP1575515A4
(de)
*
|
2002-08-29 |
2007-08-08 |
Genentech Inc |
Achaete-scute-ähnliche 2 polypeptide und kodierende nukleinsäuren und verfahren zur diagnose und behandlung eines tumors
|
HUE027196T2
(hu)
*
|
2002-09-06 |
2016-10-28 |
Genentech Inc |
Eljárás fehérjeextrakcióra
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
WO2004035608A2
(en)
*
|
2002-10-18 |
2004-04-29 |
Abgenix, Inc. |
System and method for cleaving antibodies
|
MXPA05004870A
(es)
*
|
2002-11-08 |
2005-11-04 |
Hematech Llc |
Ungulados transgenicos que tienen actividad reducida de la proteina prion y sus usos.
|
NZ540895A
(en)
|
2003-01-09 |
2007-03-30 |
Genentech Inc |
Purification of polypeptides with ethacridine lactate
|
WO2004078999A1
(en)
*
|
2003-03-05 |
2004-09-16 |
Genetic Technologies Limited |
Identification of fetal dna and fetal cell markers in maternal plasma or serum
|
WO2004087761A1
(ja)
*
|
2003-03-31 |
2004-10-14 |
Kirin Beer Kabushiki Kaisha |
ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
|
LT2335725T
(lt)
|
2003-04-04 |
2017-01-25 |
Genentech, Inc. |
Didelės koncentracijos antikūno ir baltymo kompozicijos
|
UA99933C2
(ru)
|
2003-04-09 |
2012-10-25 |
Дженентек, Инк. |
Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
|
WO2005000896A2
(en)
*
|
2003-05-30 |
2005-01-06 |
Genentech, Inc. |
Polypeptides that bind an anti-tissue factor antibody and uses thereof
|
CN1829741A
(zh)
|
2003-05-30 |
2006-09-06 |
健泰科生物技术公司 |
利用抗-vegf抗体的治疗
|
JP2007536896A
(ja)
|
2003-06-05 |
2007-12-20 |
ジェネンテック・インコーポレーテッド |
Blysアンタゴニストとその用途
|
US20050163782A1
(en)
*
|
2003-06-27 |
2005-07-28 |
Biogen Idec Ma Inc. |
Modified binding molecules comprising connecting peptides
|
EP2277908A3
(de)
|
2003-07-08 |
2011-12-14 |
Genentech, Inc. |
Heterologe IL-17A/F-Polypeptide, Antikörper und deren therapeutische Verwendungen
|
WO2005037869A2
(en)
*
|
2003-10-15 |
2005-04-28 |
Applera Corporation |
Method of reducing leachate from protein a affinity media
|
AU2004285928B2
(en)
*
|
2003-10-24 |
2012-02-02 |
Amgen, Inc. |
Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
|
ES2697327T3
(es)
|
2003-11-06 |
2019-01-23 |
Seattle Genetics Inc |
Compuesto intermedio para la preparación de conjugados que comprenden derivados de auristatina y un enlazador
|
US20050214805A1
(en)
*
|
2003-11-10 |
2005-09-29 |
Q-Rna, Inc. |
Methods of detection employing immuno-Q-Amp technology
|
DK2161283T3
(da)
|
2003-11-17 |
2014-09-01 |
Genentech Inc |
SAMMENSÆTNINGER OMFATTENDE ANTISTOFFER MOD CD79b, SOM ER KONJUGERET TIL ET VÆKSTINHIBERENDE MIDDEL ELLER ET CYTOTOKSISK MIDDEL, OG FREMGANGSMÅDER TIL BEHANDLING AF TUMOR AF HÆMATOPOIETISK OPRINDELSE
|
US20060095211A1
(en)
*
|
2003-12-05 |
2006-05-04 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
System and method for modulating a cell mediated immune response
|
US20060047436A1
(en)
*
|
2004-08-25 |
2006-03-02 |
Ishikawa Muriel Y |
System and method for magnifying an immune response
|
US20060047435A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Ishikawa Muriel Y |
System and method related to augmenting an immune system
|
US20060047434A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Ishikawa Muriel Y |
System and method related to improving an immune system
|
US20060122784A1
(en)
*
|
2004-12-03 |
2006-06-08 |
Ishikawa Muriel Y |
System and method for augmenting a humoral immune response
|
US20060182742A1
(en)
*
|
2004-08-24 |
2006-08-17 |
Ishikawa Muriel Y |
System and method for magnifying a humoral immune response
|
US20060047437A1
(en)
*
|
2004-08-25 |
2006-03-02 |
Ishikawa Muriel Y |
System and method for heightening an immune response
|
US20060122783A1
(en)
*
|
2004-08-24 |
2006-06-08 |
Ishikawa Muriel Y |
System and method for heightening a humoral immune response
|
US20060116824A1
(en)
*
|
2004-12-01 |
2006-06-01 |
Ishikawa Muriel Y |
System and method for modulating a humoral immune response
|
EP1715948B1
(de)
*
|
2004-01-20 |
2016-11-23 |
Pall Corporation |
Chromatographisches material zur absorption von proteinen bei physiologischer ionenstärke
|
WO2005087812A1
(en)
*
|
2004-03-05 |
2005-09-22 |
Ludwig Institute For Cancer Research |
Multivalent antibody materials and methods for vegf/pdgf family of growth factors
|
CN1961003B
(zh)
|
2004-03-31 |
2013-03-27 |
健泰科生物技术公司 |
人源化抗TGF-β抗体
|
JP2007532680A
(ja)
*
|
2004-04-16 |
2007-11-15 |
ジェネンテック・インコーポレーテッド |
疾患の治療方法
|
JP2007532681A
(ja)
*
|
2004-04-16 |
2007-11-15 |
ジェネンテック・インコーポレーテッド |
B細胞の枯渇を増大させる方法
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
EP1749102A4
(de)
*
|
2004-04-22 |
2009-02-25 |
Kirin Pharma Kk |
Transgene tiere und verwendungen davon
|
MXPA06014065A
(es)
|
2004-06-01 |
2007-01-31 |
Genentech Inc |
Conjugados de droga-anticuerpo y metodos.
|
CN1993143A
(zh)
|
2004-06-04 |
2007-07-04 |
健泰科生物技术公司 |
用于治疗多发性硬化的方法
|
NZ552956A
(en)
|
2004-07-20 |
2010-03-26 |
Genentech Inc |
Inhibitors of angiopoietin-like 4 protein (ANGPTL4), combinations, and their use for treating cancer
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
US8603824B2
(en)
|
2004-07-26 |
2013-12-10 |
Pfenex, Inc. |
Process for improved protein expression by strain engineering
|
US20070288173A1
(en)
*
|
2004-08-24 |
2007-12-13 |
Searete Llc, A Limited Liability Corporation Of The State Of Delware |
Computational methods and systems to reinforce a humoral immune response
|
US20060047439A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
System and method for improving a humoral immune response
|
US20070265788A1
(en)
*
|
2004-08-24 |
2007-11-15 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems for augmenting cell-mediated immune response
|
US20070207492A1
(en)
*
|
2004-08-24 |
2007-09-06 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems to adjust a humoral immune response
|
US20070196362A1
(en)
*
|
2004-08-24 |
2007-08-23 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems to bolster an immune response
|
US20070265817A1
(en)
*
|
2004-08-24 |
2007-11-15 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational systems and methods relating to fortifying an immune system
|
US20070198196A1
(en)
*
|
2004-08-24 |
2007-08-23 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational systems and methods relating to ameliorating an immune system
|
US20070265787A1
(en)
*
|
2004-08-24 |
2007-11-15 |
Searete Llc,A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems for magnifying cell-mediated immune response
|
US20070265818A1
(en)
*
|
2004-08-24 |
2007-11-15 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems for heightening cell-mediated immune response
|
US20070265819A1
(en)
*
|
2004-08-24 |
2007-11-15 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems for improving cell-mediated immune response
|
US20060051347A1
(en)
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
AU2005299701B2
(en)
|
2004-10-21 |
2011-11-17 |
Genentech, Inc. |
Method for treating intraocular neovascular diseases
|
WO2006074399A2
(en)
*
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
EP2230517A1
(de)
|
2005-01-07 |
2010-09-22 |
Diadexus, Inc. |
OVR110-Antikörperzusammensetzungen und Verwendungsverfahren dafür
|
CA2592177A1
(en)
|
2005-01-21 |
2006-07-27 |
Genentech, Inc. |
Fixed dosing of her antibodies
|
BRPI0606542A8
(pt)
|
2005-02-23 |
2018-03-20 |
Genentech Inc |
métodos para aumentar o tempo de progressão de uma doença (ttp)
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
WO2006096861A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
|
CN104610422A
(zh)
|
2005-03-11 |
2015-05-13 |
惠氏公司 |
弱分配层析的方法
|
NZ563273A
(en)
|
2005-04-09 |
2010-02-26 |
Fusion Antibodies Ltd |
Cathepsin S antibody
|
WO2006132788A2
(en)
|
2005-06-06 |
2006-12-14 |
Genentech, Inc. |
Transgenic models for different genes and their use for gene characterization
|
CA2614436C
(en)
|
2005-07-07 |
2016-05-17 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
|
US8871720B2
(en)
*
|
2005-07-07 |
2014-10-28 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
|
EP1922410A2
(de)
|
2005-08-15 |
2008-05-21 |
Genentech, Inc. |
Genunterbrechungen, zusammensetzungen und verfahren in verbindung damit
|
US7612181B2
(en)
*
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
KR20140053410A
(ko)
|
2005-08-19 |
2014-05-07 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
EP2500357A3
(de)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
EP2230256A1
(de)
*
|
2005-09-23 |
2010-09-22 |
Walter Reed Army Institute of Research (WRAIR) |
Antikörper mit simultanen Subsite-Eigenschaften gegenüber Proteinen und Fettepitopen
|
US7422899B2
(en)
*
|
2005-10-05 |
2008-09-09 |
Biogen Idec Ma Inc. |
Antibodies to the human prolactin receptor
|
ES2618785T3
(es)
|
2005-10-31 |
2017-06-22 |
Oncomed Pharmaceuticals, Inc. |
Composiciones y métodos para tratar el cáncer basados en receptores FZD humanos
|
US20070161089A1
(en)
*
|
2005-11-08 |
2007-07-12 |
Genentech, Inc. |
Method of Producing Pan-Specific Antibodies
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
EP1962584A2
(de)
|
2005-11-21 |
2008-09-03 |
Genentech, Inc. |
Neuartige genunterbrechung, dazugehörige zusammensetzungen und verfahren
|
US7737259B2
(en)
|
2005-12-02 |
2010-06-15 |
Genentech, Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling
|
EP1973948B1
(de)
|
2005-12-15 |
2015-02-11 |
Genentech, Inc. |
Verfahren und zusammensetzungen zum targeting von polyubiquitin
|
US7625759B2
(en)
*
|
2005-12-19 |
2009-12-01 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
CA2638785C
(en)
|
2006-01-05 |
2017-02-21 |
Genentech, Inc. |
Anti-ephb4 antibodies and methods using same
|
JP2009527227A
(ja)
|
2006-02-17 |
2009-07-30 |
ジェネンテック・インコーポレーテッド |
遺伝子破壊、それに関連する組成物および方法
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
ES2544957T3
(es)
|
2006-03-21 |
2015-09-07 |
Genentech, Inc. |
Terapia combinada que implica antagonistas alfa5beta1
|
AU2007227224A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Anti-tumor cell antigen antibody therapeutics
|
NZ596517A
(en)
|
2006-04-05 |
2013-06-28 |
Abbott Biotech Ltd |
Antibody purification
|
EP2007428A2
(de)
|
2006-04-05 |
2008-12-31 |
Genentech, Inc. |
Verfahren zur verwendung von boc/cdo zur modulation der hedgehog-signalisierung
|
DE102006017701A1
(de)
*
|
2006-04-15 |
2007-10-25 |
Degussa Gmbh |
Silicium-Titan-Mischoxidpulver, Dispersion hiervon und daraus hergestellter titanhaltiger Zeolith
|
JP2009536022A
(ja)
|
2006-04-19 |
2009-10-08 |
ジェネンテック・インコーポレーテッド |
新規の遺伝子破壊、それに関連する組成物および方法
|
US20090142259A1
(en)
*
|
2006-05-12 |
2009-06-04 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
|
US8524865B2
(en)
|
2006-05-30 |
2013-09-03 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
EP2049570B1
(de)
*
|
2006-06-01 |
2016-08-10 |
President and Fellows of Harvard College |
Reinigung von bivalent aktiven antikörpern, mit verwendung von einem nicht-chromatographischen verfahren
|
US8874380B2
(en)
|
2010-12-09 |
2014-10-28 |
Rutgers, The State University Of New Jersey |
Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
|
JP5829004B2
(ja)
|
2006-06-30 |
2015-12-09 |
ノボ・ノルデイスク・エー/エス |
抗nkg2a抗体とその使用
|
WO2008011081A2
(en)
|
2006-07-19 |
2008-01-24 |
The Trustees Of The University Of Pennsylvania |
Wsx-1/p28 as a target for anti-inflammatory responses
|
AU2007284651B2
(en)
|
2006-08-09 |
2014-03-20 |
Institute For Systems Biology |
Organ-specific proteins and methods of their use
|
US20100292090A1
(en)
|
2006-08-25 |
2010-11-18 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
DK2059533T3
(da)
|
2006-08-30 |
2013-02-25 |
Genentech Inc |
Multispecifikke antistoffer
|
US8911964B2
(en)
|
2006-09-13 |
2014-12-16 |
Abbvie Inc. |
Fed-batch method of making human anti-TNF-alpha antibody
|
SG174804A1
(de)
|
2006-09-13 |
2011-10-28 |
Abbott Lab |
|
US20080076139A1
(en)
|
2006-09-21 |
2008-03-27 |
Sharat Singh |
Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
|
MX2009003229A
(es)
*
|
2006-09-29 |
2009-06-18 |
Oncomed Pharm Inc |
Composiciones y metodos para diagnosticar y tratar cancer.
|
TWI414531B
(zh)
*
|
2006-10-12 |
2013-11-11 |
Genentech Inc |
淋巴毒素α之抗體
|
KR101541550B1
(ko)
|
2006-10-27 |
2015-08-04 |
제넨테크, 인크. |
항체 및 면역접합체 및 이들의 용도
|
EP2078039B1
(de)
*
|
2006-11-01 |
2017-09-13 |
Biogen MA Inc. |
Verfahren zur isolierung von biomakromolekülen mithilfe divalenter kationen mit geringem ph-wert
|
US20080108147A1
(en)
*
|
2006-11-03 |
2008-05-08 |
Tie Wei |
Reduction of non-specific binding in immunoassays
|
US8470332B2
(en)
|
2006-11-22 |
2013-06-25 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
AU2007325283B2
(en)
|
2006-11-27 |
2012-08-30 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
US20090186034A1
(en)
*
|
2006-12-19 |
2009-07-23 |
Genetech, Inc. |
Gene expression markers for inflammatory bowel disease
|
US9127064B2
(en)
|
2006-12-21 |
2015-09-08 |
Novo Nordisk A/S |
Antibodies against human NKG2D and uses thereof
|
US20080171344A1
(en)
*
|
2006-12-22 |
2008-07-17 |
Kapsner Kenneth P |
Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase
|
WO2008079849A2
(en)
*
|
2006-12-22 |
2008-07-03 |
Genentech, Inc. |
Antibodies to insulin-like growth factor receptor
|
ES2426158T3
(es)
|
2007-01-22 |
2013-10-21 |
Genentech, Inc. |
Precipitación con polielectrolito y purificación de anticuerpos
|
EP2106439B1
(de)
|
2007-01-24 |
2014-11-12 |
The Regents of the University of Michigan |
Zusammensetzungen und verfahren zur behandlung und diagnostizierung von pankreaskrebs
|
US20100119526A1
(en)
*
|
2007-01-26 |
2010-05-13 |
Bioinvent International Ab |
DLL4 Signaling Inhibitors and Uses Thereof
|
RU2009133784A
(ru)
|
2007-02-09 |
2011-03-20 |
Дженентек, Инк. (Us) |
АНТИ-Robo4-АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
|
EP2121753A2
(de)
*
|
2007-02-14 |
2009-11-25 |
Amgen, Inc |
Verfahren zur isolation von antikörpern durch ausscheidung
|
EP2436781B1
(de)
|
2007-02-22 |
2015-10-07 |
Genentech, Inc. |
Verfahren für den Nachweis von entzündlicher Darmerkrankung
|
CA2677108A1
(en)
|
2007-03-02 |
2008-09-12 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
EP2134360B1
(de)
|
2007-03-14 |
2015-11-18 |
Takeda Vaccines, Inc. |
Reinigung virusähnlicher partikel
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
EP2142651B1
(de)
|
2007-04-27 |
2013-05-22 |
Pfenex Inc. |
Schnellscreeningverfahren für bakterienwirte zur identifizierung bestimmter stämme mit verbessertem ertrag und/oder verbesserter qualität bei der expression heterologer proteine
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
US8263081B2
(en)
|
2007-05-14 |
2012-09-11 |
The University Of Chicago |
Antibody-light fusion products for cancer therapeutics
|
CA3006428A1
(en)
|
2007-06-08 |
2008-12-18 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
US8158758B2
(en)
|
2007-07-02 |
2012-04-17 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for treating and diagnosing cancer
|
ES2528922T3
(es)
|
2007-07-16 |
2015-02-13 |
Genentech, Inc. |
Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
|
KR101486615B1
(ko)
|
2007-07-16 |
2015-01-28 |
제넨테크, 인크. |
항-cd79b 항체 및 면역접합체 및 사용 방법
|
CN101952312A
(zh)
*
|
2007-07-31 |
2011-01-19 |
米迪缪尼有限公司 |
多特异性表位结合蛋白及其应用
|
EP2190861A4
(de)
|
2007-08-22 |
2011-03-30 |
Univ California |
Aktivierbare bindende polypeptide und verfahren zu deren identifikation und anwendung
|
CN101835894A
(zh)
|
2007-08-24 |
2010-09-15 |
肿瘤疗法科学股份有限公司 |
Ebi3、dlx5、nptx1和cdkn3用作肺癌治疗和诊断的靶基因
|
JP2010536844A
(ja)
|
2007-08-24 |
2010-12-02 |
オンコセラピー・サイエンス株式会社 |
癌の治療標的及び診断マーカーとしてのdkk1癌遺伝子
|
WO2009028521A1
(en)
|
2007-08-24 |
2009-03-05 |
Oncotherapy Science, Inc. |
Pkib and naaladl2 for target genes of prostate cancer therapy and diagnosis
|
CA2700714C
(en)
|
2007-09-26 |
2018-09-11 |
Ucb Pharma S.A. |
Dual specificity antibody fusions
|
CA2700701C
(en)
|
2007-09-26 |
2020-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substitution in cdr
|
US8691222B2
(en)
|
2007-10-02 |
2014-04-08 |
Genentech, Inc. |
NLRR-1 antagonists and uses thereof
|
US20090149638A1
(en)
*
|
2007-10-03 |
2009-06-11 |
Ley Arthur C |
Systems and methods for purifying proteins
|
DK2233149T3
(en)
|
2007-10-16 |
2016-05-17 |
Zymogenetics Inc |
COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE
|
KR20140015166A
(ko)
|
2007-10-30 |
2014-02-06 |
제넨테크, 인크. |
양이온 교환 크로마토그래피에 의한 항체 정제
|
ES2560532T3
(es)
|
2007-11-02 |
2016-02-19 |
Novartis Ag |
Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (LRP6)
|
JP5985150B2
(ja)
|
2007-11-07 |
2016-09-06 |
ジェネンテック, インコーポレイテッド |
微生物障害の処置のための組成物および方法
|
KR20100097691A
(ko)
*
|
2007-11-12 |
2010-09-03 |
테라클론 사이언시스, 아이엔씨. |
인플루엔자의 치료 및 진단을 위한 조성물 및 방법
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
MX2010005893A
(es)
|
2007-11-29 |
2011-03-04 |
Genentech Inc Star |
Marcadores de expresion genica para enfermedad inflamatoria de intestino.
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗-vegf抗體
|
GB0723797D0
(en)
*
|
2007-12-05 |
2008-01-16 |
Immunosolv Ltd |
Method
|
PT2227483T
(pt)
|
2007-12-19 |
2017-06-21 |
Henry M Jackson Found Advancement Military Medicine Inc |
Formas solúveis da glicoproteína f de vírus hendra e nipah e suas utilizações
|
US7914785B2
(en)
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
EP2077281A1
(de)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
|
AR070141A1
(es)
*
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
BRPI0908508A2
(pt)
|
2008-01-24 |
2016-03-22 |
Novo Nordisk As |
anticorpo monoclonal nkg2a anti-humano humanizado
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
TWI607019B
(zh)
|
2008-01-31 |
2017-12-01 |
建南德克公司 |
抗-cd79b抗體及免疫共軛物及使用方法
|
MX2010008874A
(es)
|
2008-02-14 |
2010-09-22 |
Bristol Myers Squibb Co |
Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico.
|
DK2250498T3
(da)
|
2008-02-25 |
2013-02-04 |
Nestec Sa |
Lægemiddelvalg til brystcancerterapi under anvendelse af antistof-baserede arrays
|
WO2009111644A2
(en)
*
|
2008-03-05 |
2009-09-11 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
ES2542308T3
(es)
|
2008-03-10 |
2015-08-04 |
Theraclone Sciences, Inc. |
Composiciones y métodos para la terapia y diagnóstico de infecciones por citomegalovirus
|
CA2718975A1
(en)
|
2008-04-10 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
AU2009236653B2
(en)
*
|
2008-04-16 |
2014-09-25 |
Biogen Ma Inc. |
Method of isolating biomacromolecules using polyalkylene glycol and transition metals
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
US9029508B2
(en)
|
2008-04-29 |
2015-05-12 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
WO2009136892A1
(en)
|
2008-05-09 |
2009-11-12 |
Akonni Biosystems |
Microarray system
|
US8680025B2
(en)
*
|
2008-05-09 |
2014-03-25 |
Akonni Biosystems, Inc. |
Microarray system
|
US8093018B2
(en)
|
2008-05-20 |
2012-01-10 |
Otsuka Pharmaceutical Co., Ltd. |
Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
|
EP2291399B1
(de)
|
2008-05-22 |
2014-06-25 |
Bristol-Myers Squibb Company |
Polyvalente proteine mit fibronectin-gerüstdomänen
|
CN102112494A
(zh)
|
2008-06-03 |
2011-06-29 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
EP3002299A1
(de)
*
|
2008-06-03 |
2016-04-06 |
AbbVie Inc. |
Dual-variable- domain-immunglobuline und ihre verwendungen
|
EP2313507A2
(de)
*
|
2008-07-03 |
2011-04-27 |
Pfenex Inc |
Screening-verfahren mit hohem durchsatz und verwendung davon zur identifizierung einer produktionsplattform für ein multifunktionelles bindungsprotein
|
MX2011000236A
(es)
|
2008-07-08 |
2011-02-24 |
Oncomed Pharm Inc |
Agentes de union a notch y antagonistas y metodos de uso de los mismos.
|
KR20110031369A
(ko)
*
|
2008-07-08 |
2011-03-25 |
아보트 러보러터리즈 |
프로스타글란딘 e2 이원 가변 도메인 면역글로불린 및 이의 용도
|
JP5986745B2
(ja)
|
2008-07-15 |
2016-09-06 |
アカデミア シニカAcademia Sinica |
Ptfe様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
|
EP2815766B1
(de)
|
2008-08-05 |
2017-07-05 |
Novartis AG |
Zusammensetzungen und Verfahren für auf das Komplementprotein C5 gerichtete Antikörper
|
WO2010019702A2
(en)
|
2008-08-12 |
2010-02-18 |
Oncomed Pharmaceuticals, Inc. |
Ddr1-binding agents and methods of use thereof
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
WO2010027981A1
(en)
*
|
2008-09-03 |
2010-03-11 |
Genentech, Inc. |
Multispecific antibodies
|
MX2011002372A
(es)
|
2008-09-10 |
2011-04-04 |
Genentech Inc |
Composiciones y metodos para la prevencion de la degradacion oxidativa de proteinas.
|
TW201438738A
(zh)
*
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
BRPI0918947A2
(pt)
*
|
2008-09-26 |
2015-12-01 |
Ucb Pharma Sa |
proteína de fusão de anticorpo
|
GB0818228D0
(en)
|
2008-10-06 |
2008-11-12 |
Avecia Biolog Ltd |
Purification process
|
KR102100066B1
(ko)
|
2008-10-14 |
2020-04-10 |
제넨테크, 인크. |
이뮤노글로불린 변이체 및 그의 용도
|
BRPI0920027A2
(pt)
*
|
2008-10-20 |
2015-10-06 |
Abbott Lab |
isolamento e purificação de anticorpos usando cromatografia de afinidade a proteína a
|
KR101722423B1
(ko)
|
2008-10-20 |
2017-04-18 |
애브비 인코포레이티드 |
항체 정제 동안의 바이러스 불활성화
|
RS55784B1
(sr)
|
2008-11-11 |
2017-07-31 |
Univ Michigan Regents |
Anti-cxcr1 kompozicije i postupci
|
EP2346529B1
(de)
|
2008-11-12 |
2016-02-10 |
Theraclone Sciences, Inc. |
Humane m2e-peptid-immunogene
|
CN104922669A
(zh)
|
2008-11-13 |
2015-09-23 |
通用医疗公司 |
用于通过调整bmp-6来调节铁稳态的方法和组合物
|
SI2361085T2
(sl)
|
2008-11-22 |
2018-11-30 |
F. Hoffmann-La Roche Ag |
Uporaba protitelesa proti vegf v kombinaciji s kemoterapijo za zdravljenje raka dojk
|
WO2010062858A1
(en)
*
|
2008-11-26 |
2010-06-03 |
Allergan, Inc. |
Il-17 antibody inhibitor for treating dry eye
|
US8211434B2
(en)
*
|
2008-11-26 |
2012-07-03 |
Allergan, Inc. |
KLK-13 antibody inhibitor for treating dry eye
|
EP2373692A4
(de)
*
|
2008-12-04 |
2013-11-20 |
Abbvie Inc |
Immunglobuline mit zweifacher variabler domäne und ihre verwendung
|
TWI686405B
(zh)
|
2008-12-09 |
2020-03-01 |
建南德克公司 |
抗pd-l1抗體及其於增進t細胞功能之用途
|
WO2010080528A1
(en)
|
2008-12-17 |
2010-07-15 |
Genentech, Inc. |
Hepatitis c virus combination therapy
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
US20120009182A1
(en)
|
2008-12-23 |
2012-01-12 |
Genentech, Inc. |
Immunoglobulin variants with altered binding to protein a
|
US20110142836A1
(en)
*
|
2009-01-02 |
2011-06-16 |
Olav Mella |
B-cell depleting agents for the treatment of chronic fatigue syndrome
|
BRPI1006141B8
(pt)
|
2009-01-12 |
2021-05-25 |
Cytomx Therapeutics Llc |
composições de anticorpo modificado, métodos para preparar e usar as mesmas
|
GB0902916D0
(en)
|
2009-02-20 |
2009-04-08 |
Fusion Antibodies Ltd |
Antibody therapy
|
WO2010095031A2
(en)
*
|
2009-02-23 |
2010-08-26 |
Glenmark Pharmaceuticals S.A. |
Humanized antibodies that bind to cd19 and their uses
|
JP5861223B2
(ja)
*
|
2009-02-23 |
2016-02-16 |
サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. |
プロタンパク質およびその使用方法
|
GB0903168D0
(en)
|
2009-02-25 |
2009-04-08 |
Fusion Antibodies Ltd |
Diagnostic method and kit
|
RU2015132478A
(ru)
|
2009-03-05 |
2015-12-10 |
Эббви Инк. |
Связывающие il-17 белки
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
US20120121596A1
(en)
|
2009-03-20 |
2012-05-17 |
Germaine Fuh |
Bispecific anti-her antibodies
|
JP5757534B2
(ja)
|
2009-03-25 |
2015-07-29 |
ジェネンテック, インコーポレイテッド |
抗fgfr3抗体およびこれを用いた方法
|
AR075925A1
(es)
|
2009-03-25 |
2011-05-04 |
Genentech Inc |
Anticuerpos anti-alfa5beta1 (alfa5beta1: glicoproteina integrina) y sus usos
|
JP5681166B2
(ja)
|
2009-03-31 |
2015-03-04 |
スリーエム イノベイティブ プロパティズ カンパニー |
疎水性モノマー、疎水的に誘導体化された支持体、並びにその製造及び使用方法
|
BRPI1012676A2
(pt)
|
2009-04-01 |
2016-04-05 |
Genentech Inc |
anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
|
EP2413967A1
(de)
|
2009-04-01 |
2012-02-08 |
F. Hoffmann-La Roche AG |
Behandlung von insulinresistenten erkrankungen
|
CN102369215B
(zh)
|
2009-04-02 |
2015-01-21 |
罗切格利卡特公司 |
包含全长抗体和单链Fab片段的多特异性抗体
|
WO2010115932A1
(en)
|
2009-04-08 |
2010-10-14 |
Novartis Ag |
Combination for the treatment of bone loss
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
US9447467B2
(en)
|
2009-04-21 |
2016-09-20 |
Genetic Technologies Limited |
Methods for obtaining fetal genetic material
|
US9062116B2
(en)
|
2009-04-23 |
2015-06-23 |
Infinity Pharmaceuticals, Inc. |
Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
|
WO2010124163A2
(en)
*
|
2009-04-23 |
2010-10-28 |
Theraclone Sciences, Inc. |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
EP2424567B1
(de)
*
|
2009-04-27 |
2018-11-21 |
OncoMed Pharmaceuticals, Inc. |
Verfahren zur herstellung von heteromultimeren molekülen
|
JP2012527473A
(ja)
|
2009-05-20 |
2012-11-08 |
セラクローン サイエンシーズ, インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
US8680055B2
(en)
|
2009-06-03 |
2014-03-25 |
University Of Southern California |
Methods for decreasing steroidogenesis in prostate cancer cells
|
CA2766737A1
(en)
|
2009-07-07 |
2011-01-13 |
Genentech, Inc. |
Diagnosis and treatment of autoimmune demyelinating diseases
|
CA2768013C
(en)
|
2009-07-15 |
2018-08-21 |
Prometheus Laboratories Inc. |
Drug selection for gastric cancer therapy using antibody-based arrays
|
JP2012533322A
(ja)
|
2009-07-20 |
2012-12-27 |
ジェネンテック, インコーポレイテッド |
クローン病のための遺伝子発現マーカー
|
CA2768617C
(en)
|
2009-07-24 |
2018-03-27 |
Akonni Biosystems |
Flow cell device
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
TW201109438A
(en)
*
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
US20110027275A1
(en)
|
2009-07-31 |
2011-02-03 |
Napoleone Ferrara |
Inhibition of tumor metastasis
|
EP2462158B1
(de)
|
2009-08-06 |
2018-01-10 |
F. Hoffmann-La Roche AG |
Verfahren zur verbesserung der entfernung von viren bei der proteinreinigung
|
EP2464657B1
(de)
|
2009-08-10 |
2015-04-01 |
MorphoSys AG |
Neue screening-verfahren zur identifizierung von antikörpern und deren fragmente, die ein antigen mit enzymatischer aktivität binden
|
KR101822205B1
(ko)
|
2009-08-11 |
2018-01-25 |
제넨테크, 인크. |
글루타민-비함유 세포 배양 배지에서의 단백질의 생성
|
US20110038871A1
(en)
|
2009-08-11 |
2011-02-17 |
Veena Viswanth |
Ccr2 inhibitors for treating conditions of the eye
|
CN102573909A
(zh)
|
2009-08-15 |
2012-07-11 |
霍夫曼-拉罗奇有限公司 |
抗血管发生疗法用于治疗先前治疗过的乳腺癌
|
CN102741288B
(zh)
|
2009-08-29 |
2015-08-19 |
Abbvie公司 |
治疗用dll4结合蛋白
|
JP2013503607A
(ja)
|
2009-09-01 |
2013-02-04 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリンおよびその使用
|
EP2473522B1
(de)
|
2009-09-02 |
2016-08-17 |
Genentech, Inc. |
Smoothened-mutant und verfahren zu seiner anwendung
|
US20120302737A1
(en)
|
2009-09-16 |
2012-11-29 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
ES2530732T3
(es)
|
2009-09-17 |
2015-03-05 |
Hoffmann La Roche |
Procedimientos de diagnóstico para el cáncer de pulmón
|
US8470552B2
(en)
*
|
2009-10-12 |
2013-06-25 |
Keck Graduate Institute |
Strategy to reduce lactic acid production and control PH in animal cell culture
|
AR078651A1
(es)
|
2009-10-15 |
2011-11-23 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
ES2895226T3
(es)
|
2009-10-16 |
2022-02-18 |
Mereo Biopharma 5 Inc |
Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
|
CA2777934A1
(en)
|
2009-10-20 |
2011-04-28 |
Prometheus Laboratories Inc. |
Proximity-mediated assays for detecting oncogenic fusion proteins
|
BR112012009409A2
(pt)
|
2009-10-22 |
2017-02-21 |
Genentech Inc |
método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
|
RU2559533C2
(ru)
|
2009-10-22 |
2015-08-10 |
Дженентек, Инк. |
Антитела против гепсина и способы их применения
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
CN102812040A
(zh)
|
2009-10-30 |
2012-12-05 |
雅培制药有限公司 |
Sorf构建体和多基因表达
|
WO2011051466A1
(en)
|
2009-11-02 |
2011-05-05 |
Novartis Ag |
Anti-idiotypic fibronectin-based binding molecules and uses thereof
|
EP2496600A1
(de)
|
2009-11-04 |
2012-09-12 |
Fabrus LLC |
Verfahren zur optimierung von antikörpern auf der basis von affinitätsreifung
|
SI2496601T1
(sl)
*
|
2009-11-05 |
2017-09-29 |
F. Hoffmann-La Roche Ag |
Tehnike in sestavek za sekrecijo heterolognih polipeptidov
|
CN103755809B
(zh)
|
2009-11-30 |
2016-06-01 |
霍夫曼-拉罗奇有限公司 |
治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
MX2012006406A
(es)
|
2009-12-04 |
2012-07-25 |
Genentech Inc |
Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
|
WO2011071577A1
(en)
|
2009-12-11 |
2011-06-16 |
Genentech, Inc. |
Anti-vegf-c antibodies and methods using same
|
US20110226650A1
(en)
|
2009-12-21 |
2011-09-22 |
Genentech, Inc. |
Antibody formulation
|
CA2784385A1
(en)
|
2009-12-23 |
2011-06-30 |
Genentech, Inc. |
Anti-bv8 antibodies and uses thereof
|
GB0922553D0
(en)
|
2009-12-23 |
2010-02-10 |
Fusion Antibodies Ltd |
Prognostic marker
|
ES2701626T3
(es)
|
2009-12-28 |
2019-02-25 |
Oncotherapy Science Inc |
Anticuerpos anti-CDH3 y sus usos
|
MX2012008085A
(es)
|
2010-01-13 |
2012-09-12 |
Oncomed Pharm Inc |
Agentes de union notch1 y metodos de uso de los mismos.
|
ES2551871T3
(es)
|
2010-01-29 |
2015-11-24 |
Morphosys Ag |
Genotecas combinatorias de anticuerpos de roedor
|
NZ601743A
(en)
|
2010-02-12 |
2014-11-28 |
Oncomed Pharm Inc |
Methods for identifying and isolating cells expressing a polypeptide
|
TW201437228A
(zh)
|
2010-02-23 |
2014-10-01 |
Genentech Inc |
用於診斷及治療腫瘤之組合物及方法
|
CN103237810A
(zh)
|
2010-02-23 |
2013-08-07 |
霍夫曼-拉罗奇有限公司 |
用于治疗卵巢癌的抗血管发生疗法
|
KR20190114019A
(ko)
|
2010-02-24 |
2019-10-08 |
이뮤노젠 아이엔씨 |
엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
|
RU2016146198A
(ru)
|
2010-03-02 |
2018-12-19 |
Эббви Инк. |
Терапевтические dll4-связывающие белки
|
SG183542A1
(en)
|
2010-03-12 |
2012-10-30 |
Immunogen Inc |
Cd37-binding molecules and immunoconjugates thereof
|
MX354867B
(es)
|
2010-03-22 |
2018-03-23 |
Genentech Inc Star |
Composiciones y métodos útiles para estabilizar formulaciones que contienen proteína.
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
AU2011239935A1
(en)
|
2010-04-16 |
2012-11-08 |
Novartis Ag |
Methods and compositions for improving implant osseointegration
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
CA2796633C
(en)
|
2010-04-23 |
2020-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
SG185027A1
(en)
|
2010-05-03 |
2012-11-29 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
JP2013525484A
(ja)
|
2010-05-03 |
2013-06-20 |
ジェネンテック, インコーポレイテッド |
タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
|
AU2011249783B9
(en)
|
2010-05-06 |
2014-11-06 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (LRP6) antibodies
|
US9290573B2
(en)
|
2010-05-06 |
2016-03-22 |
Novartis Ag |
Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
|
AU2011250970B2
(en)
|
2010-05-10 |
2016-12-15 |
Sinica, Academia |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
ES2635594T3
(es)
|
2010-05-14 |
2017-10-04 |
Abbvie Inc. |
Proteínas de unión a IL-1
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
WO2011150110A1
(en)
|
2010-05-25 |
2011-12-01 |
Genentech, Inc. |
Methods of purifying polypeptides
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
RU2613886C2
(ru)
|
2010-06-03 |
2017-03-21 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
|
WO2011156369A2
(en)
*
|
2010-06-07 |
2011-12-15 |
Dr. Reddy's Laboratories Ltd. |
Purification of modified cytokines
|
US20110311527A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
|
CA2802756C
(en)
|
2010-06-24 |
2021-05-04 |
Genentech, Inc. |
Compositions and methods for stabilizing protein-containing formulations
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
WO2012012750A1
(en)
|
2010-07-23 |
2012-01-26 |
Trustees Of Boston University |
ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
|
NZ607480A
(en)
|
2010-08-03 |
2014-10-31 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
WO2012019024A2
(en)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
EP2420250A1
(de)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4-Antikörper
|
WO2012021786A2
(en)
|
2010-08-12 |
2012-02-16 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
EP2603525A1
(de)
|
2010-08-13 |
2013-06-19 |
F.Hoffmann-La Roche Ag |
Antikörper gegen il-1beta und il-18 zur behandlung von krankheiten
|
JP2013537416A
(ja)
|
2010-08-13 |
2013-10-03 |
メディミューン リミテッド |
変異型Fc領域を含むモノマーポリペプチド及び使用方法
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
WO2012024663A1
(en)
*
|
2010-08-20 |
2012-02-23 |
Ge Healthcare Limited |
Quality control devices and methods for radiopharmaceuticals
|
DK2606070T3
(en)
|
2010-08-20 |
2017-03-27 |
Novartis Ag |
Antibodies for the epidermal growth factor receptor 3 (HER3)
|
BR112013001847A2
(pt)
|
2010-08-24 |
2016-05-31 |
Hoffmann La Roche |
anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica
|
EP2608803A4
(de)
|
2010-08-26 |
2014-01-15 |
Abbvie Inc |
Immunglobuline mit zweifacher variabler domäne und ihre verwendung
|
PT3556396T
(pt)
|
2010-08-31 |
2022-07-04 |
Scripps Research Inst |
Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
|
WO2012030512A1
(en)
*
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
WO2012032043A1
(en)
|
2010-09-07 |
2012-03-15 |
Areva Med Llc |
212 pb imaging
|
KR20130096731A
(ko)
|
2010-09-08 |
2013-08-30 |
할로자임, 아이엔씨 |
조건부 활성 치료적 단백질을 평가,확인 또는 진화시키는 방법
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
EP3223014B1
(de)
*
|
2010-09-24 |
2018-12-05 |
Full Spectrum Genetics, Inc. |
Verfahren zur analyse von bindungsinteraktionen
|
EP2625197B1
(de)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Smoothened-mutant und verfahren zu seiner anwendung
|
AR083546A1
(es)
|
2010-10-25 |
2013-03-06 |
Genentech Inc |
Tratamiento de inflamacion gastrointestinal, soriasis y asma
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
EP2643353A1
(de)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispezifische moleküle
|
WO2012075333A2
(en)
|
2010-12-02 |
2012-06-07 |
Prometheus Laboratories Inc. |
Her2delta16 peptides
|
WO2012121775A2
(en)
|
2010-12-21 |
2012-09-13 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
JP2014503821A
(ja)
|
2010-12-23 |
2014-02-13 |
ネステク ソシエテ アノニム |
抗体ベースのアレイを用いる悪性がんの療法のための薬剤選択
|
CA2822684A1
(en)
|
2010-12-23 |
2012-06-28 |
Intercell Austria Ag |
Oprf/i agents and their use in hospitalized and other patients
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
CN103547288B
(zh)
|
2011-01-10 |
2016-03-16 |
密执安大学评议会 |
干细胞因子抑制剂
|
US20150018408A1
(en)
|
2013-07-10 |
2015-01-15 |
The Regents Of The University Of Michigan |
Therapeutic antibodies and uses thereof
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
CA2825064C
(en)
|
2011-02-04 |
2022-08-30 |
Genentech, Inc. |
Fc variants and methods for their production
|
CA2827301A1
(en)
|
2011-02-14 |
2012-08-23 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
WO2012119989A2
(en)
|
2011-03-04 |
2012-09-13 |
Oryzon Genomics, S.A. |
Methods and antibodies for the diagnosis and treatment of cancer
|
JP6385060B2
(ja)
|
2011-03-07 |
2018-09-05 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
治療的に活性な抗体のインビボにおける選択
|
EP2683290B1
(de)
|
2011-03-07 |
2018-11-07 |
F.Hoffmann-La Roche Ag |
Verfahren zum in-vivo-testen von therapeutischen antikörpern
|
ES2666301T3
(es)
|
2011-03-09 |
2018-05-03 |
Cell Signaling Technology, Inc. |
Métodos y reactivos para crear anticuerpos monoclonales
|
JP2014509591A
(ja)
|
2011-03-15 |
2014-04-21 |
セラクローン サイエンシーズ, インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
AU2012237026A1
(en)
|
2011-03-25 |
2013-10-24 |
Genentech, Inc. |
Novel protein purification methods
|
CN103608038A
(zh)
|
2011-03-31 |
2014-02-26 |
弗·哈夫曼-拉罗切有限公司 |
施用β7整联蛋白拮抗剂的方法
|
CN103945864A
(zh)
|
2011-04-25 |
2014-07-23 |
先进生物学实验室股份有限公司 |
截短的hiv包膜蛋白(env)、其相关方法和组合物
|
US9062106B2
(en)
|
2011-04-27 |
2015-06-23 |
Abbvie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
EP2702408A1
(de)
|
2011-04-29 |
2014-03-05 |
Novartis AG |
Verfahren zur behandlung von plattenepithelkarzinom, zugehörige anwendungen
|
JP6024025B2
(ja)
|
2011-05-02 |
2016-11-09 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
少容量投与用のアロタイプ選択抗体の限外濾過濃縮
|
US20140141458A1
(en)
|
2011-05-12 |
2014-05-22 |
The Johns Hopkins University |
Assay reagents for a neurogranin diagnostic kit
|
IL295205A
(en)
|
2011-05-17 |
2022-10-01 |
Univ Rockefeller |
Neutralizing antibodies against the human immunodeficiency virus and methods of using them
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
EP2540828A1
(de)
|
2011-06-30 |
2013-01-02 |
Gene Signal International SA |
Zusammensetzung mit Inhibitoren von IRS-1 und VEGF
|
CN108159426A
(zh)
|
2011-06-30 |
2018-06-15 |
基因信号国际公司 |
含有irs-1抑制剂和vegf抑制剂的组合物
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
CA2840460C
(en)
|
2011-07-11 |
2022-08-16 |
Glenmark Pharmaceuticals S.A. |
Antibodies that bind to ox40 and their uses
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
US9890207B2
(en)
|
2011-07-25 |
2018-02-13 |
California Institute Of Technology |
Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
|
US9493549B2
(en)
|
2011-07-25 |
2016-11-15 |
The Rockefeller University |
Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
|
EA026924B1
(ru)
|
2011-08-01 |
2017-05-31 |
Дженентек, Инк. |
Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
|
KR20140068877A
(ko)
|
2011-08-17 |
2014-06-09 |
제넨테크, 인크. |
불응성 종양에서의 혈관신생의 억제
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
WO2013033623A1
(en)
|
2011-09-02 |
2013-03-07 |
Nestec S.A. |
Profiling of signal pathway proteins to determine therapeutic efficacy
|
HUE061002T2
(hu)
|
2011-09-23 |
2023-04-28 |
Mereo Biopharma 5 Inc |
VEGF/DLL4-kötõ ágensek és alkalmazásaik
|
US9575073B2
(en)
|
2011-10-10 |
2017-02-21 |
Rutgers, The State University Of New Jersey |
Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
|
WO2013055958A1
(en)
|
2011-10-11 |
2013-04-18 |
Genentech, Inc. |
Improved assembly of bispecific antibodies
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
WO2013055908A1
(en)
|
2011-10-12 |
2013-04-18 |
The Scripps Research Institute |
An hiv-1 gp120 mini v3 loop and uses thereof
|
JP2014530816A
(ja)
|
2011-10-14 |
2014-11-20 |
ノバルティスアーゲー |
Wnt経路関連疾患のための抗体および方法
|
EP2581388A1
(de)
|
2011-10-14 |
2013-04-17 |
Centre National de la Recherche Scientifique (CNRS) |
Antikörper gegen sPLA2-V und Gebrauch davon
|
TW201323440A
(zh)
|
2011-10-24 |
2013-06-16 |
Abbvie Inc |
抗骨硬化素(sclerostin)之免疫結合物
|
EP2771361A1
(de)
|
2011-10-24 |
2014-09-03 |
AbbVie Inc. |
Bispezifische gegen tnf und il17 gerichtete immunbinder
|
ES2637423T5
(es)
|
2011-11-02 |
2022-03-17 |
Hoffmann La Roche |
Cromatografía de sobrecarga y elución
|
EP2797957B1
(de)
|
2011-11-23 |
2019-06-19 |
MedImmune, LLC |
Her3-spezifische bindungsmoleküle und verwendungen davon
|
DK2785375T3
(da)
|
2011-11-28 |
2020-10-12 |
Merck Patent Gmbh |
Anti-pd-l1-antistoffer og anvendelser deraf
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
CN108341873B
(zh)
|
2011-12-05 |
2022-03-25 |
诺华股份有限公司 |
表皮生长因子受体3(her3)的抗体
|
EA201491107A1
(ru)
|
2011-12-05 |
2014-11-28 |
Новартис Аг |
Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
|
EP2602265A1
(de)
|
2011-12-07 |
2013-06-12 |
Centre National de la Recherche Scientifique (CNRS) |
Antikörper gegen Anti-sPLA2-X und Verwendungen damit
|
JP2015501839A
(ja)
|
2011-12-15 |
2015-01-19 |
ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago |
受容体に対する親和性が増大した変異型light分子を使用する癌療法のための方法および組成物
|
BR112014015111A2
(pt)
|
2011-12-21 |
2017-06-13 |
Novartis Ag |
composições e processos para anticorpos que se direcionam ao fator p
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
AU2012355356B2
(en)
|
2011-12-22 |
2017-10-12 |
Genentech, Inc. |
Ion exchange membrane chromatography
|
EP2797955A2
(de)
|
2011-12-30 |
2014-11-05 |
AbbVie Inc. |
Immunglobuline mit zweifacher variabler domäne gegen il-13 und/oder il-17
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
US20150011431A1
(en)
|
2012-01-09 |
2015-01-08 |
The Scripps Research Institute |
Humanized antibodies
|
US20140050720A1
(en)
|
2012-01-09 |
2014-02-20 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
JP2015506950A
(ja)
|
2012-01-31 |
2015-03-05 |
ジェネンテック, インコーポレイテッド |
抗ig−em1’抗体およびそれを用いる方法
|
JP6486686B2
(ja)
|
2012-02-10 |
2019-03-20 |
ジェネンテック, インコーポレイテッド |
単鎖抗体及び他のヘテロ多量体
|
KR20170036142A
(ko)
|
2012-03-08 |
2017-03-31 |
할로자임, 아이엔씨 |
조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법
|
EP2641916A1
(de)
|
2012-03-23 |
2013-09-25 |
Centre National de la Recherche Scientifique (C.N.R.S) |
Neue Antikörper gegen Anti-sPLA2-IIA und Verwendungen damit
|
WO2013144758A1
(en)
|
2012-03-27 |
2013-10-03 |
Novartis Ag |
Treatment of fibrosis
|
JP2015514710A
(ja)
|
2012-03-27 |
2015-05-21 |
ジェネンテック, インコーポレイテッド |
Her3阻害剤に関する診断及び治療
|
EP2833900B1
(de)
|
2012-04-01 |
2018-09-19 |
Technion Research & Development Foundation Limited |
Extrazelluläre matrix-metalloproteasen-induktor (emmprin)-peptide und bindende antikörper
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
WO2013176754A1
(en)
*
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
BR112014029887A8
(pt)
|
2012-05-31 |
2021-09-14 |
Genentech Inc |
Método para tratar ou retardar a progressão do câncer, kits e uso de um antagonista de ligação do eixo pd-1, oxaliplatina, leucovorina e 5-fu
|
CA2873998A1
(en)
|
2012-06-04 |
2013-12-12 |
Irm Llc |
Site-specific labeling methods and molecules produced thereby
|
US20130344064A1
(en)
|
2012-06-08 |
2013-12-26 |
Glenmark Pharmaceuticals S.A. |
Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
|
WO2013192589A1
(en)
|
2012-06-21 |
2013-12-27 |
California Institute Of Technology |
Antibodies targeting hiv escape mutants
|
JOP20130186B1
(ar)
|
2012-06-22 |
2021-08-17 |
Takeda Vaccines Montana Inc |
تنقية الجزيئات الشبيهة بالفيروسات
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
RU2639287C2
(ru)
|
2012-06-27 |
2017-12-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
|
UY34905A
(es)
|
2012-07-12 |
2014-01-31 |
Abbvie Inc |
Proteínas de unión a il-1
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
WO2014022332A1
(en)
|
2012-07-31 |
2014-02-06 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
US9297806B2
(en)
|
2012-08-01 |
2016-03-29 |
The Johns Hopkins University |
5-hydroxymethylcytosine in human cancer
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
US9914956B2
(en)
|
2012-08-18 |
2018-03-13 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
PL2888590T3
(pl)
|
2012-08-21 |
2020-11-30 |
Janssen Pharmaceutica Nv |
Przeciwciała dla olanzapiny i ich zastosowanie
|
JP2015529199A
(ja)
|
2012-08-21 |
2015-10-05 |
オルソ−クリニカル ダイアグノスティクス,インコーポレイティド |
パリペリドンハプテンに対する抗体及びその使用
|
ES2762105T3
(es)
|
2012-08-21 |
2020-05-22 |
Janssen Pharmaceutica Nv |
Anticuerpos para aripiprazol y uso de los mismos
|
CN104755929B
(zh)
|
2012-08-21 |
2016-11-09 |
奥索临床诊断有限公司 |
喹硫平的抗体及其用途
|
AU2013305895B2
(en)
|
2012-08-21 |
2017-10-19 |
Saladax Biomedical Inc. |
Antibodies to olanzapine haptens and use thereof
|
EP2888238A4
(de)
|
2012-08-21 |
2016-01-27 |
Academia Sinica |
Benzocyclooctynverbindungen und verwendungen davon
|
US9611332B2
(en)
|
2012-08-21 |
2017-04-04 |
Janssen Pharmaceutica Nv |
Antibodies to aripiprazole haptens and use thereof
|
CN109970637B
(zh)
|
2012-08-21 |
2022-04-19 |
詹森药业有限公司 |
阿立哌唑半抗原及其在免疫测定中的应用
|
PT2888286T
(pt)
|
2012-08-21 |
2018-05-09 |
Janssen Pharmaceutica Nv |
Anticorpos para haptenos de quetiapina e sua utilização
|
AU2013305965B2
(en)
|
2012-08-21 |
2017-08-24 |
Saladax Biomedical Inc. |
Antibodies to paliperidone and use thereof
|
JP6339569B2
(ja)
|
2012-08-21 |
2018-06-06 |
ヤンセン ファーマシューティカ エヌ.ベー. |
リスペリドンへの抗体及びその使用
|
US9751953B2
(en)
|
2012-08-21 |
2017-09-05 |
Janssen Pharmaceutica Nv |
Antibodies to risperidone haptens and use thereof
|
SG11201500938XA
(en)
|
2012-08-31 |
2015-04-29 |
Immunogen Inc |
Diagnostic assays and kits for detection of folate receptor 1
|
WO2014035475A1
(en)
|
2012-09-02 |
2014-03-06 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
ES2807173T3
(es)
|
2012-09-10 |
2021-02-22 |
Int Aids Vaccine Initiative |
Inmunógenos de anticuerpos ampliamente neutralizantes del VIH-1, métodos de generación y usos de los mismos
|
DK2908912T3
(da)
|
2012-10-18 |
2020-10-26 |
Univ Rockefeller |
Bredt neutraliserende anti-hiv-antistoffer
|
WO2014071018A1
(en)
|
2012-10-31 |
2014-05-08 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a dll4 antagonist
|
SG11201503412RA
(en)
|
2012-11-01 |
2015-05-28 |
Abbvie Inc |
Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
|
CA2890979A1
(en)
|
2012-11-15 |
2014-05-22 |
Genentech, Inc. |
Ionic strength-mediated ph gradient ion exchange chromatography
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
SG11201503567SA
(en)
|
2012-12-05 |
2015-06-29 |
Novartis Ag |
Compositions and methods for antibodies targeting epo
|
CA2891686A1
(en)
|
2012-12-18 |
2014-06-26 |
Novartis Ag |
Compositions and methods that utilize a peptide tag that binds to hyaluronan
|
US9458244B2
(en)
|
2012-12-28 |
2016-10-04 |
Abbvie Inc. |
Single chain multivalent binding protein compositions and methods
|
JP2016510319A
(ja)
|
2012-12-28 |
2016-04-07 |
アッヴィ・インコーポレイテッド |
多価結合タンパク質組成物
|
WO2014106602A1
(en)
|
2013-01-02 |
2014-07-10 |
Glenmark Pharmaceuticals S.A. |
Antibodies that bind to tl1a and their uses
|
EP2948177A1
(de)
|
2013-01-22 |
2015-12-02 |
AbbVie Inc. |
Verfahren zur optimierung der domänenstabilität von bindungsproteinen
|
WO2014116846A2
(en)
|
2013-01-23 |
2014-07-31 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
WO2014118705A1
(en)
|
2013-01-31 |
2014-08-07 |
Novartis Ag |
Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
|
WO2014120975A1
(en)
|
2013-02-01 |
2014-08-07 |
California Institute Of Technology |
Antibody-mediated immunocontraception
|
SI2953976T1
(sl)
|
2013-02-08 |
2021-08-31 |
Novartis Ag |
Specifična mesta z modificiranje protiteles za izdelavo imunokonjugatov
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
MX369175B
(es)
|
2013-02-25 |
2019-10-30 |
Genentech Inc |
Métodos para detectar mutantes de akt resistentes a fármacos.
|
WO2014142117A1
(ja)
|
2013-03-12 |
2014-09-18 |
全薬工業株式会社 |
抗ブドウ球菌抗体、その製造方法並びにその使用
|
EP2830651A4
(de)
|
2013-03-12 |
2015-09-02 |
Abbvie Inc |
An humanes tnf-alpha bindende humane antikörper und verfahren zur herstellung davon
|
SI2968467T1
(sl)
|
2013-03-13 |
2020-11-30 |
F. Hoffmann-La Roche Ag |
Pripravki z zmanjšano oksidacijo
|
US10023608B1
(en)
|
2013-03-13 |
2018-07-17 |
Amgen Inc. |
Protein purification methods to remove impurities
|
EP2970468B1
(de)
|
2013-03-13 |
2021-07-07 |
Novartis AG |
Notch2-bindungsmoleküle zur behandlung von atemwegserkrankungen
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
AR095398A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida
|
CN104968362B
(zh)
|
2013-03-13 |
2018-12-14 |
霍夫曼-拉罗奇有限公司 |
氧化降低的配制剂
|
AR095399A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida, método
|
SG10201913932VA
(en)
|
2013-03-13 |
2020-03-30 |
Genentech Inc |
Antibody formulations
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
CN105378099B
(zh)
|
2013-03-14 |
2021-05-11 |
雅培制药有限公司 |
Hcv核心脂质结合结构域单克隆抗体
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
WO2014159239A2
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Antibodies against notch 3
|
CA2906421C
(en)
|
2013-03-14 |
2022-08-16 |
George J. Dawson |
Hcv antigen-antibody combination assay and methods and compositions for use therein
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
US9790478B2
(en)
|
2013-03-14 |
2017-10-17 |
Abbott Laboratories |
HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
|
NZ710929A
(en)
|
2013-03-15 |
2018-02-23 |
Novartis Ag |
Antibody drug conjugates
|
KR102202476B1
(ko)
|
2013-03-15 |
2021-01-12 |
제넨테크, 인크. |
세포 배양 배지 및 항체 생산 방법
|
BR112015021993A8
(pt)
|
2013-03-15 |
2019-12-03 |
Genentech Inc |
polipeptídeo, métodos para sua produção, métodos para cultivo de uma célula, composição farmacêutica, kit, e meio de cultura celular
|
WO2014145208A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Hydrophobic interaction protein chromatography under no-salt conditions
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
MX2015013166A
(es)
|
2013-03-15 |
2015-12-11 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
|
RU2015145610A
(ru)
|
2013-03-27 |
2017-05-04 |
Дженентек, Инк. |
Применение биомаркеров для оценки лечения желудочно-кишечных воспалительных расстройств антагонистами бета7 интегрина
|
EP2983710B1
(de)
|
2013-04-09 |
2019-07-31 |
Annexon, Inc. |
Behandlungsverfahren für neuromyelitis optica
|
MX368142B
(es)
|
2013-04-30 |
2019-09-20 |
Intas Pharmaceuticals Ltd |
Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
|
RU2015155552A
(ru)
|
2013-05-24 |
2017-06-27 |
Нестек С.А. |
Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника
|
AU2014278537B2
(en)
|
2013-06-12 |
2018-04-19 |
The General Hospital Corporation |
Methods, kits, and systems for multiplexed detection of target molecules and uses thereof
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
UY35620A
(es)
|
2013-06-21 |
2015-01-30 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
TWI596107B
(zh)
|
2013-06-25 |
2017-08-21 |
卡地拉保健有限公司 |
單株抗體之新穎純化方法
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
WO2014210564A1
(en)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Glycan conjugates and use thereof
|
EP3019523A4
(de)
|
2013-07-09 |
2016-12-28 |
Annexon Inc |
Verfahren zur behandlung von morbus alzheimer und morbus huntington
|
CA2918052A1
(en)
|
2013-07-12 |
2015-01-15 |
Genentech, Inc. |
Elucidation of ion exchange chromatography input optimization
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
RU2019129525A
(ru)
|
2013-07-16 |
2019-11-05 |
Дженентек, Инк. |
Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
CA2918370A1
(en)
|
2013-07-18 |
2015-01-22 |
Fabrus, Inc. |
Humanized antibodies with ultralong complementarity determining regions
|
JP6463359B2
(ja)
|
2013-08-12 |
2019-01-30 |
ジェネンテック, インコーポレイテッド |
補体関連病態を治療するための組成物及び方法
|
IL293871A
(en)
|
2013-08-30 |
2022-08-01 |
Immunogen Inc |
Antibodies and assays for the detection of folate receptor 1
|
MX2016002798A
(es)
|
2013-09-05 |
2016-07-21 |
Genentech Inc |
Metodo para reutilizacion de cromatografia.
|
EP3041484B1
(de)
|
2013-09-06 |
2021-03-03 |
Academia Sinica |
Humane inkt-zell-aktivierung mittels glykolipiden mit veränderten glycosylgruppen
|
KR102651018B1
(ko)
|
2013-09-11 |
2024-03-27 |
이글 바이오로직스 인코퍼레이티드 |
점도저하제를 함유하는 액체 단백질 제형
|
CA2922562A1
(en)
|
2013-09-12 |
2015-03-19 |
Halozyme, Inc. |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
RU2016107435A
(ru)
|
2013-09-13 |
2017-10-18 |
Дженентек, Инк. |
Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
|
EP3043820A4
(de)
|
2013-09-13 |
2017-07-12 |
F. Hoffmann-La Roche AG |
Verfahren und zusammensetzungen mit gereinigten rekombinanten polypeptiden
|
HUE047194T2
(hu)
|
2013-09-27 |
2020-04-28 |
Hoffmann La Roche |
Anti-PDL1 antitest készítmények
|
US9243294B2
(en)
|
2013-09-30 |
2016-01-26 |
Hadasit Medical Research Services And Development Ltd. |
Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
SG11201602522VA
(en)
|
2013-10-02 |
2016-04-28 |
Medimmune Llc |
Neutralizing anti-influenza a antibodies and uses thereof
|
WO2015051293A2
(en)
|
2013-10-04 |
2015-04-09 |
Abbvie, Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
MX2016006726A
(es)
|
2013-11-25 |
2016-12-16 |
Ccam Biotherapeutics Ltd |
Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
|
JP6620094B2
(ja)
|
2013-11-26 |
2019-12-11 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
免疫応答を調節するための組成物および方法
|
EP3611191A1
(de)
|
2013-12-09 |
2020-02-19 |
Allakos Inc. |
Anti-siglec-8-antikörper und verfahren zur verwendung davon
|
JP2017505756A
(ja)
|
2013-12-13 |
2017-02-23 |
ザ ジェネラル ホスピタル コーポレイション |
可溶性高分子量(hmw)タウ種およびその用途
|
MX2016007972A
(es)
|
2013-12-17 |
2016-10-28 |
Genentech Inc |
Metodos para tratar canceres con antagonistas de union al eje pd-1 y taxanos.
|
PT3082877T
(pt)
|
2013-12-17 |
2019-12-03 |
Novartis Ag |
Péptidos citotóxicos e seus conjugados
|
CA2934028A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
CN105899535A
(zh)
|
2013-12-17 |
2016-08-24 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
|
RU2020129339A
(ru)
|
2013-12-20 |
2020-10-02 |
Дженентек, Инк. |
Антитела с двойной специфичностью
|
US10188650B2
(en)
|
2014-01-03 |
2019-01-29 |
The Regents Of The University Of Michigan |
Treatment of neurological disorders
|
EP2891657A1
(de)
|
2014-01-07 |
2015-07-08 |
Centre National de la Recherche Scientifique (CNRS) |
Durch ionische Flüssigkeiten unterstützte Organozinnreagenzien zur Herstellung von radioaktiven Arzneimittelverbindungen
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
TW201620939A
(zh)
|
2014-01-16 |
2016-06-16 |
中央研究院 |
治療及檢測癌症之組合物及方法
|
EP2896400A1
(de)
|
2014-01-17 |
2015-07-22 |
Université Catholique De Louvain |
Verfahren zur Erhöhung der Bioverfügbarkeit von inhaliertem Verbindungen
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
AU2015214264B2
(en)
|
2014-02-04 |
2018-12-20 |
Curis, Inc. |
Mutant Smoothened and methods of using the same
|
WO2015120130A1
(en)
|
2014-02-07 |
2015-08-13 |
Novartis Ag |
Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
|
EP3782630A1
(de)
|
2014-02-19 |
2021-02-24 |
University of Tennessee Research Foundation |
Antikörper zum verschieben des geschlechtsverhältnisses und verwendungsverfahren dafür
|
DK3110446T3
(da)
|
2014-02-28 |
2022-02-28 |
Allakos Inc |
Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
|
EA201691827A1
(ru)
|
2014-03-12 |
2017-01-30 |
Новартис Аг |
Конкретные участки для модификации антител с целью получения иммуноконъюгатов
|
JP6644717B2
(ja)
|
2014-03-14 |
2020-02-12 |
ジェネンテック, インコーポレイテッド |
異種ポリペプチドを分泌させるための方法及び組成物
|
EP3119913B1
(de)
|
2014-03-21 |
2021-01-06 |
The Brigham and Women's Hospital, Inc. |
Verfahren und zusammensetzungen zur behandlung von immunbedingten erkrankungen oder störungen und/oder therapieüberwachung
|
US20170174764A1
(en)
|
2014-03-27 |
2017-06-22 |
Yeda Research And Development Co. Ltd. |
T-cell receptor cdr3 peptides and antibodies
|
EP3122377A4
(de)
|
2014-03-27 |
2018-03-14 |
F.Hoffmann-La Roche Ag |
Verfahren zur diagnose und behandlung von entzündlicher darmerkrankung
|
CN106415244B
(zh)
|
2014-03-27 |
2020-04-24 |
中央研究院 |
反应性标记化合物及其用途
|
CN106132439A
(zh)
|
2014-03-31 |
2016-11-16 |
豪夫迈·罗氏有限公司 |
包含抗血管发生剂和ox40结合激动剂的组合疗法
|
HUE051676T2
(hu)
|
2014-04-08 |
2021-03-29 |
Boston Pharmaceuticals Inc |
Il-21-re specifikus kötõ molekulák és alkalmazásaik
|
JP2017512765A
(ja)
|
2014-04-11 |
2017-05-25 |
メディミューン,エルエルシー |
二重特異性her2抗体
|
AU2015249666A1
(en)
|
2014-04-25 |
2016-11-17 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for treating subjects with immune-mediated diseases
|
WO2015164364A2
(en)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
CR20160534A
(es)
|
2014-04-27 |
2017-04-25 |
Ccam Biotherapeutics Ltd |
Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1)
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
HRP20231139T1
(hr)
|
2014-05-06 |
2024-01-05 |
F. Hoffmann - La Roche Ag |
Proizvodnja heteromultimernih proteina upotrebom stanica sisavaca
|
EP3143138B1
(de)
|
2014-05-13 |
2022-03-23 |
BioAtla, Inc. |
Bedingt aktive biologische proteine
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
KR102576850B1
(ko)
|
2014-05-27 |
2023-09-11 |
아카데미아 시니카 |
박테로이드 기원의 푸코시다제 및 이의 사용 방법
|
KR102512592B1
(ko)
|
2014-05-27 |
2023-03-21 |
아카데미아 시니카 |
항-her2 글리코항체 및 이의 용도
|
EP3149036A4
(de)
|
2014-05-27 |
2017-12-27 |
Academia Sinica |
Anti-cd20-glycoantikörper und verwendungen davon
|
AU2015267044A1
(en)
|
2014-05-28 |
2016-12-15 |
Academia Sinica |
Anti-TNF-alpha glycoantibodies and uses thereof
|
EP3148581B1
(de)
|
2014-05-30 |
2019-10-09 |
Henlius Biotech Co., Ltd. |
Anti-egfr-antikörper
|
US20160002326A1
(en)
|
2014-06-10 |
2016-01-07 |
Abbvie Inc. |
Compositions and methods for treating rheumatoid arthritis
|
KR20170016479A
(ko)
|
2014-06-13 |
2017-02-13 |
노파르티스 아게 |
아우리스타틴 유도체 및 그의 접합체
|
ES2694296T3
(es)
|
2014-06-17 |
2018-12-19 |
Centre National De La Recherche Scientifique (Cnrs) |
Anticuerpos monoclonales anti-pVHL y usos de los mismos
|
WO2015198240A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
WO2015198243A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
US10398765B2
(en)
|
2014-07-03 |
2019-09-03 |
Yale University |
Dickkopf2 (Dkk2) inhibition suppresses tumor formation
|
CA2954508A1
(en)
|
2014-07-15 |
2016-01-21 |
Genentech, Inc. |
Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
WO2016011167A1
(en)
|
2014-07-16 |
2016-01-21 |
Dana-Farber Cancer Institute, Inc., Et Al |
Her3 inhibition in low-grade serous ovarian cancers
|
WO2016014360A1
(en)
|
2014-07-24 |
2016-01-28 |
Genentech, Inc. |
Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
WO2016020882A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoetin-like 4 (angptl4) antibodies and methods of use
|
DK3177642T3
(da)
|
2014-08-07 |
2022-02-21 |
Novartis Ag |
Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
|
EP4066859A1
(de)
|
2014-08-08 |
2022-10-05 |
Alector LLC |
Anti-trem2-antikörper und verfahren zur verwendung davon
|
AU2015302959B2
(en)
|
2014-08-12 |
2018-09-20 |
Novartis Ag |
Anti-CDH6 antibody drug conjugates
|
AU2015308818B2
(en)
|
2014-08-28 |
2021-02-25 |
Bioatla Llc |
Conditionally active chimeric antigen receptors for modified T-cells
|
PL3186281T3
(pl)
|
2014-08-28 |
2019-10-31 |
Halozyme Inc |
Terapia skojarzona enzymem rozkładającym hialuronian i inhibitorem punktu kontrolnego odpowiedzi immunologicznej
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
JP2017532019A
(ja)
|
2014-09-03 |
2017-11-02 |
バイオアトラ、エルエルシー |
同じ真核細胞産生宿主における条件的活性型生物学的タンパク質の発見及び作製
|
CN107001404B
(zh)
|
2014-09-08 |
2021-06-29 |
中央研究院 |
使用醣脂激活人类iNKT细胞
|
EP3191592A1
(de)
|
2014-09-11 |
2017-07-19 |
Novartis AG |
Hemmung von prmt5 zur behandlung von erkrankungen im zusammenhang mit mtap-mangel
|
EP3193932B1
(de)
|
2014-09-15 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antikörperformulierungen
|
US10222386B2
(en)
|
2014-09-19 |
2019-03-05 |
The Johns Hopkins University |
Biomarkers of congnitive dysfunction
|
TWI700300B
(zh)
|
2014-09-26 |
2020-08-01 |
日商中外製藥股份有限公司 |
中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體
|
US11471479B2
(en)
|
2014-10-01 |
2022-10-18 |
Eagle Biologics, Inc. |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
EA201700181A1
(ru)
|
2014-10-14 |
2017-09-29 |
Галозим, Инк. |
Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
|
WO2016070051A2
(en)
|
2014-10-31 |
2016-05-06 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
WO2016073685A1
(en)
|
2014-11-05 |
2016-05-12 |
Annexon, Inc. |
Humanized anti-complement factor c1q antibodies and uses thereof
|
KR102544705B1
(ko)
|
2014-11-05 |
2023-06-15 |
제넨테크, 인크. |
박테리아 내 2쇄 단백질을 생산하는 방법
|
EP3215533A2
(de)
|
2014-11-05 |
2017-09-13 |
F. Hoffmann-La Roche AG |
Anti-fgfr2/3-antikörper und verfahren zur verwendung davon
|
CN108064308B
(zh)
|
2014-11-05 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
细菌中产生双链蛋白的方法
|
EP3215519A1
(de)
|
2014-11-06 |
2017-09-13 |
Novartis AG |
Amatoxinderivate und konjugate davon als inhibitoren der rna-polymerase
|
AU2015343494A1
(en)
|
2014-11-06 |
2017-04-27 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and TIGIT inhibitors
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
LT3218406T
(lt)
|
2014-11-10 |
2021-06-25 |
Medimmune Limited |
Surišančios molekulės, specifiškos cd73 ir jų panaudojimas
|
EP3217787B1
(de)
|
2014-11-10 |
2019-04-17 |
F.Hoffmann-La Roche Ag |
Tiermodell für nephropathie und mittel zur behandlung davon
|
JP6929771B2
(ja)
|
2014-11-10 |
2021-09-01 |
ジェネンテック, インコーポレイテッド |
抗インターロイキン−33抗体及びその使用
|
EP3789403A1
(de)
|
2014-11-11 |
2021-03-10 |
MedImmune Limited |
Therapeutische kombinationen mit anti-cd73-antikörpern und a2a-rezeptorinhibitoren sowie verwendungen davon
|
US9526768B2
(en)
|
2014-11-13 |
2016-12-27 |
Jennifer Mai |
Compositions for the treatment of cancer
|
WO2016081384A1
(en)
|
2014-11-17 |
2016-05-26 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
CN107257805A
(zh)
|
2014-11-19 |
2017-10-17 |
雀巢产品技术援助有限公司 |
抗血清素、色氨酸和犬尿氨酸代谢产物的抗体及其用途
|
EP3221445B1
(de)
|
2014-11-20 |
2021-07-14 |
The Regents of The University of California |
Zusammensetzungen und verfahren in zusammenhang mit hämatologischer erholung
|
US10479997B2
(en)
|
2014-12-01 |
2019-11-19 |
Novartis Ag |
Compositions and methods for diagnosis and treatment of prostate cancer
|
EP3227341A1
(de)
|
2014-12-02 |
2017-10-11 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Anti-mutante calreticulin-antikörper und deren verwendung bei der diagnose und therapie von myeloiden malignomen
|
ES2764111T3
(es)
|
2014-12-03 |
2020-06-02 |
Hoffmann La Roche |
Anticuerpos multiespecíficos
|
EP3029032A1
(de)
|
2014-12-05 |
2016-06-08 |
Centre National de la Recherche Scientifique (CNRS) |
Bifunktionelle Do2pa-Derivate, Chelate mit metallischen Kationen und Verwendung davon
|
JP2017537929A
(ja)
|
2014-12-05 |
2017-12-21 |
ジェネンテック, インコーポレイテッド |
Pd−1軸アンタゴニスト及びhpk1アンタゴニストを用いたがん治療のための方法及び組成物
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
US10703813B2
(en)
|
2014-12-19 |
2020-07-07 |
Universite De Nantes |
Anti IL-34 antibodies
|
KR20230149328A
(ko)
|
2014-12-22 |
2023-10-26 |
시스트이뮨, 인코포레이티드 |
이중특이적 4가 항체 및 이의 제조 및 사용방법
|
JP7152156B2
(ja)
|
2015-01-14 |
2022-10-12 |
ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド |
抗lapモノクローナル抗体による癌の処置
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
JP2018510844A
(ja)
|
2015-01-24 |
2018-04-19 |
アカデミア シニカAcademia Sinica |
がんマーカーおよびその使用方法
|
AU2015378564A1
(en)
|
2015-01-24 |
2017-07-13 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
CN107407677B
(zh)
|
2015-01-28 |
2020-07-17 |
豪夫迈·罗氏有限公司 |
多发性硬化的基因表达标志和治疗
|
DK3250590T3
(da)
|
2015-01-30 |
2021-10-18 |
Academia Sinica |
Sammensætninger og fremgangsmåder, der vedrører universelle glycoformer, til øget anti-SSEA4-antistofeffektivitet
|
MA41451A
(fr)
|
2015-02-04 |
2017-12-12 |
Univ Washington |
Constructions anti-tau
|
JP2018512597A
(ja)
|
2015-02-04 |
2018-05-17 |
ジェネンテック, インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
EP3256164B1
(de)
|
2015-02-09 |
2020-03-25 |
Memorial Sloan Kettering Cancer Center |
Multispezifische antikörpern mit affinität für menschliches a33-antigen und dota-metallkomplex
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
TWI691512B
(zh)
|
2015-02-20 |
2020-04-21 |
日商橘生藥品工業股份有限公司 |
Fc融合高親和性IgE受體α鏈
|
KR20170138410A
(ko)
|
2015-02-23 |
2017-12-15 |
시걸 테라퓨틱스 에스에이에스 |
비-천연 세마포린 3 및 이의 의학적 용도
|
WO2016137985A1
(en)
|
2015-02-26 |
2016-09-01 |
Merck Patent Gmbh |
Pd-1 / pd-l1 inhibitors for the treatment of cancer
|
EP3262072A1
(de)
|
2015-02-26 |
2018-01-03 |
F. Hoffmann-La Roche AG |
Integrin-beta7-antagonisten und methoden zur behandlung von morbus crohn
|
ES2761726T3
(es)
|
2015-03-06 |
2020-05-20 |
Hoffmann La Roche |
DsbA y DsbC ultrapurificadas y procedimientos de preparación y uso de las mismas
|
US20180111989A1
(en)
|
2015-04-01 |
2018-04-26 |
Hadasit Medical Research Services And Development Ltd. |
Inhibitors of neuroligin 4 - neurexin 1-beta protein-protein interaction for treatment of liver disorders
|
US11279768B1
(en)
|
2015-04-03 |
2022-03-22 |
Precision Biologics, Inc. |
Anti-cancer antibodies, combination therapies, and uses thereof
|
CA2982115A1
(en)
|
2015-04-06 |
2016-10-13 |
President And Fellows Of Harvard College |
Compositions and methods for non-myeloablative conditioning
|
SI3280441T1
(sl)
|
2015-04-07 |
2022-01-31 |
Alector Llc |
Protitelesa anti-sortilin in metoda njihove uporabe
|
CA2981183A1
(en)
|
2015-04-07 |
2016-10-13 |
Greg Lazar |
Antigen binding complex having agonistic activity and methods of use
|
US11215616B2
(en)
|
2015-04-10 |
2022-01-04 |
National Institutes Of Health (Nih), (Dhhs), U.S. Government |
Methods of determining patient populations amenable to immunomodulatory treatment of cancer
|
AU2016252773B2
(en)
|
2015-04-24 |
2022-06-02 |
Genentech, Inc. |
Multispecific antigen-binding proteins
|
WO2016172551A2
(en)
|
2015-04-24 |
2016-10-27 |
Genentech, Inc. |
Methods of identifying bacteria comprising binding polypeptides
|
EP3936524A3
(de)
|
2015-05-11 |
2022-06-15 |
F. Hoffmann-La Roche AG |
Zusammensetzungen und verfahren zur behandlung von lupus nephritis
|
EP3297674B1
(de)
|
2015-05-22 |
2023-01-04 |
Translational Drug Development Llc |
Benzamid- und wirkstoffzusammensetzungen und verfahren zur verwendung
|
WO2016191750A1
(en)
|
2015-05-28 |
2016-12-01 |
Genentech, Inc. |
Cell-based assay for detecting anti-cd3 homodimers
|
KR20180013881A
(ko)
|
2015-05-29 |
2018-02-07 |
제넨테크, 인크. |
암에서의 pd-l1 프로모터 메틸화
|
WO2016196679A1
(en)
|
2015-06-02 |
2016-12-08 |
Genentech, Inc. |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
EA201792561A1
(ru)
|
2015-06-05 |
2018-04-30 |
Новартис Аг |
Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
|
EP3302525A2
(de)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Verfahren und zusammensetzungen zur diagnose, behandlung und überwachung der behandlung von shank3-mangelbedingten erkrankungen
|
AU2016276981B2
(en)
|
2015-06-12 |
2022-10-06 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
JP2018518491A
(ja)
|
2015-06-12 |
2018-07-12 |
アレクトル エルエルシー |
抗cd33抗体及びその使用方法
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
JP6876629B2
(ja)
|
2015-06-16 |
2021-05-26 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
Pd−l1アンタゴニスト併用療法
|
EP3310385A4
(de)
|
2015-06-17 |
2018-12-19 |
Allakos Inc. |
Verfahren und zusammensetzungen zur behandlung von fibrotischen erkrankungen
|
JP6896650B2
(ja)
|
2015-06-17 |
2021-06-30 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法
|
WO2016203432A1
(en)
|
2015-06-17 |
2016-12-22 |
Novartis Ag |
Antibody drug conjugates
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
CN108473573A
(zh)
|
2015-06-29 |
2018-08-31 |
豪夫迈·罗氏有限公司 |
Ii型抗cd20抗体用于器官移植中
|
DK3313884T3
(da)
|
2015-06-29 |
2021-02-22 |
Immunogen Inc |
Anti-cd123-antistoffer og konjugater og derivater deraf
|
WO2017023866A1
(en)
|
2015-07-31 |
2017-02-09 |
Boston Biomedical, Inc. |
Method of targeting stat3 and other non-druggable proteins
|
JP6940479B2
(ja)
|
2015-08-03 |
2021-09-29 |
ノバルティス アーゲー |
Fgf21関連障害を処置する方法
|
TW202330904A
(zh)
|
2015-08-04 |
2023-08-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
CA2996059A1
(en)
|
2015-08-28 |
2017-03-09 |
Alector Llc |
Anti-siglec-7 antibodies and methods of use thereof
|
JP6861418B2
(ja)
|
2015-09-02 |
2021-04-28 |
イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド |
ヒトt細胞免疫グロブリン及びitimドメイン(tigit)に特異的な抗体
|
JP2018532990A
(ja)
|
2015-09-04 |
2018-11-08 |
オービーアイ ファーマ,インコーポレイテッド |
グリカンアレイおよび使用の方法
|
SI3347377T1
(sl)
|
2015-09-09 |
2021-06-30 |
Novartis Ag |
Protitelesa, ki vežejo timusni stromalni limfopoietin (tslp) in postopki uporabe protiteles
|
EA038332B1
(ru)
|
2015-09-09 |
2021-08-10 |
Новартис Аг |
Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
|
US10894988B2
(en)
|
2015-09-11 |
2021-01-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method of determining the prognosis of hepatocellular carcinomas using a multigene signature associated with metastasis
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
EP3353204B1
(de)
|
2015-09-23 |
2023-10-18 |
Mereo BioPharma 5, Inc. |
Bi-spezifischer anti-vegf/dll4-antikörper zur verwendung bei der behandlung von platin-resistentem eierstockkrebs
|
ES2768957T3
(es)
|
2015-09-24 |
2020-06-24 |
Abvitro Llc |
Composiciones de anticuerpos contra el VIH y métodos de uso
|
WO2017058881A1
(en)
|
2015-09-28 |
2017-04-06 |
The Trustees Of Columbia University In The City Of New York |
Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
|
WO2017058780A1
(en)
|
2015-09-30 |
2017-04-06 |
Merck Patent Gmbh |
Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
|
CN108738323B
(zh)
|
2015-10-06 |
2023-05-26 |
艾利妥 |
抗trem2抗体及其使用方法
|
WO2017062682A2
(en)
|
2015-10-06 |
2017-04-13 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
EP3362093A4
(de)
|
2015-10-13 |
2019-05-08 |
Technion Research & Development Foundation Limited |
Heparanase-neutralisierende monoklonale antikörper
|
RS63144B1
(sr)
|
2015-10-21 |
2022-05-31 |
Redcoat Solutions Inc |
Uređaj za detekciju krevetnih stenica
|
HUE063822T2
(hu)
|
2015-10-21 |
2024-02-28 |
Redcoat Solutions Inc |
Ágyi poloska elleni monoklonális antitestek és eljárások elõállításukra és alkalmazásukra
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
WO2017074774A1
(en)
|
2015-10-28 |
2017-05-04 |
Yale University |
Humanized anti-dkk2 antibody and uses thereof
|
WO2017075432A2
(en)
|
2015-10-29 |
2017-05-04 |
Alector Llc |
Anti-siglec-9 antibodies and methods of use thereof
|
SG10202103712VA
(en)
|
2015-11-10 |
2021-05-28 |
Medimmune Llc |
Binding molecules specific for asct2 and uses thereof
|
CN106729743B
(zh)
|
2015-11-23 |
2021-09-21 |
四川科伦博泰生物医药股份有限公司 |
抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
|
WO2017089593A1
(en)
|
2015-11-26 |
2017-06-01 |
Universite Paris Descartes |
Inhibitors for treating or preventing a pulmonary arterial hypertension in systemic sclerosis patients and method for diagnosing said disease
|
HUE056243T2
(hu)
|
2015-12-15 |
2022-02-28 |
Gilead Sciences Inc |
Emberi immunhiányt okozó vírust semlegesítõ ellenanyagok
|
EP3390449A1
(de)
|
2015-12-17 |
2018-10-24 |
Janssen Pharmaceutica N.V. |
Antikörper gegen risperidon und verwendung davon
|
JP6994461B2
(ja)
|
2015-12-17 |
2022-02-04 |
ヤンセン ファーマシューティカ エヌ.ベー. |
クエチアピンに対する抗体及びその使用
|
KR20180089510A
(ko)
|
2015-12-18 |
2018-08-08 |
노파르티스 아게 |
CD32b를 표적화하는 항체 및 그의 사용 방법
|
EP3395835B1
(de)
|
2015-12-25 |
2021-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Antikörper mit verbesserter aktivität und verfahren zur modifizierung davon
|
SG11201803989WA
(en)
|
2015-12-28 |
2018-06-28 |
Chugai Pharmaceutical Co Ltd |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
JP7008023B2
(ja)
|
2015-12-30 |
2022-01-25 |
ジェネンテック, インコーポレイテッド |
低減されたポリソルベート分解を有する製剤
|
MX2018008063A
(es)
|
2015-12-30 |
2018-11-29 |
Genentech Inc |
Uso de derivados de triptofano para formulaciones de proteina.
|
US10596257B2
(en)
|
2016-01-08 |
2020-03-24 |
Hoffmann-La Roche Inc. |
Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
|
EP3402819A1
(de)
|
2016-01-11 |
2018-11-21 |
Novartis AG |
Immunstimulierende humanisierte monoklonale antikörper gegen menschliches interleukin-2 und fusionsproteine davon
|
EP3405492B1
(de)
|
2016-01-21 |
2020-10-21 |
Novartis AG |
Gegen cll-1 gerichtete multispezifische moleküle
|
US11513127B2
(en)
|
2016-01-25 |
2022-11-29 |
Genentech, Inc. |
Methods for assaying T-cell dependent bispecific antibodies
|
EP3411396A1
(de)
|
2016-02-04 |
2018-12-12 |
Curis, Inc. |
Smoothened-mutant und verfahren zur verwendung davon
|
AU2017219837B2
(en)
|
2016-02-19 |
2023-08-17 |
Galapagos Nv |
Antibodies for IL-17C
|
US11066456B2
(en)
|
2016-02-25 |
2021-07-20 |
Washington University |
Compositions comprising TREM2 and methods of use thereof
|
RU2756275C2
(ru)
|
2016-03-01 |
2021-09-29 |
Юссум Рисёрч Девелопмент Компани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд. |
Антитела, специфические к рецептору полиовируса (pvr) человека
|
US10655125B2
(en)
|
2016-03-04 |
2020-05-19 |
Mor0059Us.Np |
Polypeptide library
|
WO2017152102A2
(en)
|
2016-03-04 |
2017-09-08 |
Alector Llc |
Anti-trem1 antibodies and methods of use thereof
|
EP3216458A1
(de)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modifizierter vaskulärer endothelialen wachstumsfaktor a (vegf-a) und dessen medizinische verwendung
|
JP2019515876A
(ja)
|
2016-03-08 |
2019-06-13 |
アカデミア シニカAcademia Sinica |
N−グリカンおよびそのアレイのモジュール合成のための方法
|
KR20230152153A
(ko)
|
2016-03-10 |
2023-11-02 |
악셀레론 파마 인코포레이티드 |
액티빈 타입 2 수용체 결합 단백질 및 이의 용도
|
CN116196412A
(zh)
|
2016-03-15 |
2023-06-02 |
中外制药株式会社 |
使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
AU2017236063A1
(en)
|
2016-03-23 |
2018-10-11 |
Prothix Bv |
Monoclonal antibodies against the active site of factor XI and uses thereof
|
AU2017244108B2
(en)
|
2016-03-29 |
2021-03-18 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
EP3436482A4
(de)
|
2016-03-29 |
2020-03-11 |
OBI Pharma, Inc. |
Antikörper, pharmazeutische zusammensetzungen und verfahren
|
AU2017240233B2
(en)
|
2016-03-31 |
2022-07-14 |
University Of Southern California |
A highly sensitive and specific luciferase based reporter assay for antigen detection
|
SG11201809024UA
(en)
|
2016-04-22 |
2018-11-29 |
Obi Pharma Inc |
Cancer immunotherapy by immune activation or immune modulation via globo series antigens
|
US10875919B2
(en)
|
2016-04-26 |
2020-12-29 |
Alector Llc |
Chimeric receptors and methods of use thereof
|
JP7138567B2
(ja)
|
2016-04-27 |
2022-09-16 |
ノバルティス アーゲー |
成長分化因子15に対する抗体およびそれらの使用
|
US10464969B2
(en)
|
2016-05-05 |
2019-11-05 |
Novartis Ag |
Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
|
EP4122958A1
(de)
|
2016-05-13 |
2023-01-25 |
BioAtla, Inc. |
Anti-ror2-antikörper, antikörperfragmente, deren immunkonjugate und verwendungen davon
|
MX2018014047A
(es)
|
2016-05-17 |
2019-06-20 |
Genentech Inc |
Firmas de genes estromales para el diagnóstico y uso en inmunoterapia.
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
KR20190012201A
(ko)
|
2016-05-26 |
2019-02-08 |
메르크 파텐트 게엠베하 |
암 치료용 pd-1 / pd-l1 억제제
|
EP3464354B1
(de)
|
2016-06-02 |
2021-07-28 |
Bloom Diagnostics AG |
Antikörper zur bindung an humane anti-müller-hormone (amh) und deren verwendungen
|
RU2745748C2
(ru)
|
2016-06-02 |
2021-03-31 |
Эббви Инк. |
Агонист глюкокортикоидного рецептора и его иммуноконъюгаты
|
AU2017283787B2
(en)
|
2016-06-15 |
2020-09-17 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
|
AU2017286676A1
(en)
|
2016-06-17 |
2018-12-13 |
F. Hoffmann La-Roche Ag |
Purification of multispecific antibodies
|
EP3686287A1
(de)
|
2016-06-28 |
2020-07-29 |
Hifibio |
Verfahren zur transkriptomanalyse von einzelzellen
|
EP3263706A1
(de)
|
2016-06-28 |
2018-01-03 |
Centre National De La Recherche Scientifique (Cnrs) |
Auf snat7 abzielende wirkstoffe zur behandlung von erkrankungen im zusammenhang mit der zellstoffwechselumprogrammierung
|
WO2018011691A1
(en)
|
2016-07-12 |
2018-01-18 |
Nestec S.A. |
Competitive immunoassay methods
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
AU2017302038B2
(en)
|
2016-07-27 |
2024-03-21 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
EP3491026A4
(de)
|
2016-07-29 |
2020-07-29 |
OBI Pharma, Inc. |
Menschliche antikörper, pharmazeutische zusammensetzungen und verfahren
|
EP3491022A1
(de)
|
2016-07-29 |
2019-06-05 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Antikörper gegen tumor-assoziierte makrophagen und verwendungen davon
|
US20190352426A1
(en)
|
2016-08-03 |
2019-11-21 |
Achaogen, Inc. |
Plazomicin antibodies and methods of use
|
JP2019530434A
(ja)
|
2016-08-05 |
2019-10-24 |
ジェネンテック, インコーポレイテッド |
アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
|
JP2019528312A
(ja)
|
2016-08-07 |
2019-10-10 |
ノバルティス アーゲー |
mRNA媒介性の免疫化方法
|
EP3497129A1
(de)
|
2016-08-08 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Therapeutische und diagnostische verfahren für krebs
|
WO2018035025A1
(en)
|
2016-08-15 |
2018-02-22 |
Genentech, Inc. |
Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
|
JP2019529350A
(ja)
|
2016-08-16 |
2019-10-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
混合物から個々の抗体を定量する方法
|
JP7213549B2
(ja)
|
2016-08-22 |
2023-01-27 |
シーエイチオー ファーマ インコーポレイテッド |
抗体、結合性断片、および使用の方法
|
MX2019002269A
(es)
|
2016-08-31 |
2019-09-18 |
Oncotherapy Science Inc |
Anticuerpo monoclonal contra quinasa de cremallera de leucina embrionaria materna (melk) y utilizacion del mismo.
|
US20190225682A1
(en)
|
2016-09-02 |
2019-07-25 |
180 Therapeutics Lp |
Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
|
US20190202907A1
(en)
|
2016-09-02 |
2019-07-04 |
180 Therapeutics Lp |
Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody
|
SG11201901961SA
(en)
|
2016-09-06 |
2019-04-29 |
Chugai Pharmaceutical Co Ltd |
Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
|
WO2018049083A1
(en)
|
2016-09-07 |
2018-03-15 |
The Regents Of The University Of California |
Antibodies to oxidation-specific epitopes
|
TW201825511A
(zh)
|
2016-09-09 |
2018-07-16 |
美商艾斯合顧問有限公司 |
表現免疫檢查點調節子的溶瘤病毒
|
EP3512885B1
(de)
|
2016-09-16 |
2024-02-21 |
Shanghai Henlius Biotech, Inc. |
Anti-pd-1-antikörper
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
TWI762516B
(zh)
|
2016-10-06 |
2022-05-01 |
日商腫瘤療法 科學股份有限公司 |
針對fzd10之單株抗體及其用途
|
CN109843324A
(zh)
|
2016-10-06 |
2019-06-04 |
辉瑞公司 |
用于治疗癌症的avelumab用药方案
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
AU2017350807B2
(en)
|
2016-10-25 |
2022-07-07 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for chromatography data analysis
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
CN110366558A
(zh)
|
2016-10-28 |
2019-10-22 |
班扬生物标记公司 |
针对泛素c末端水解酶l1(uch-l1)和胶质纤维酸性蛋白(gfap)的抗体及相关方法
|
EP3535396A1
(de)
|
2016-11-01 |
2019-09-11 |
Novartis AG |
Verfahren und zusammensetzungen zur verbesserung der genbearbeitung
|
US11339209B2
(en)
|
2016-11-14 |
2022-05-24 |
Novartis Ag |
Compositions, methods, and therapeutic uses related to fusogenic protein minion
|
US11000601B2
(en)
|
2016-11-21 |
2021-05-11 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
AU2017360346B2
(en)
|
2016-11-21 |
2023-11-23 |
Eirion Therapeutics, Inc. |
Transdermal delivery of large agents
|
CN110234319B
(zh)
|
2016-11-23 |
2022-09-27 |
转化药物开发有限责任公司 |
苯甲酰胺和活性化合物的组合物及其使用方法
|
KR20190080949A
(ko)
|
2016-11-23 |
2019-07-08 |
바이오버라티브 테라퓨틱스 인크. |
응고 인자 ix 및 응고 인자 x에 결합하는 이중특이적 항체
|
US10852271B2
(en)
|
2016-12-14 |
2020-12-01 |
Taiwan Semiconductor Manufacturing Co., Ltd. |
On-chip heater
|
IL267340B2
(en)
|
2016-12-15 |
2023-12-01 |
Nat Inst Biotechnology Negev Ltd |
Monoclonal antibodies against PCNA and their use
|
WO2018118780A1
(en)
*
|
2016-12-19 |
2018-06-28 |
Calico Biolabs, Inc. |
Monovalent and divalent binding proteins
|
JOP20190155A1
(ar)
|
2016-12-21 |
2019-06-23 |
Novartis Ag |
مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
|
KR20190099256A
(ko)
|
2016-12-23 |
2019-08-26 |
노파르티스 아게 |
항-인자 XI/XIa 항체를 사용한 치료 방법
|
IL267538B1
(en)
|
2016-12-23 |
2024-01-01 |
Novartis Ag |
Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
MX2019009498A
(es)
|
2017-02-08 |
2019-10-02 |
Novartis Ag |
Anticuerpos mimeticos de fgf21 y usos de los mismos.
|
US11920156B2
(en)
|
2017-02-09 |
2024-03-05 |
Indapta Therapeutics, Inc. |
Engineered natural killer (NK) cells and compositions and methods thereof
|
PE20191548A1
(es)
|
2017-02-10 |
2019-10-24 |
Genentech Inc |
Anticuerpos contra triptasa, composiciones de estos y usos de estos
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
CN108456251A
(zh)
|
2017-02-21 |
2018-08-28 |
上海君实生物医药科技股份有限公司 |
抗pd-l1抗体及其应用
|
WO2018158398A1
(en)
|
2017-03-02 |
2018-09-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to nectin-4 and uses thereof
|
LT3375889T
(lt)
|
2017-03-17 |
2020-06-25 |
Hifibio Sas |
Vienos ląstelės analizė
|
BR112019019939A2
(pt)
|
2017-03-30 |
2020-04-28 |
Merck Patent Gmbh |
combinação de anticorpo anti-pd-l1 e um inibidor de dna-pk para tratamento de câncer
|
TW201836636A
(zh)
|
2017-03-31 |
2018-10-16 |
公立大學法人奈良縣立醫科大學 |
含有替代凝血因子viii功能之多特異性抗原結合分子之用於預防和/或治療凝血因子ix異常症的醫藥組合物
|
US20190048055A1
(en)
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
US11913075B2
(en)
|
2017-04-01 |
2024-02-27 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
CA3044082A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
RU2665790C1
(ru)
|
2017-04-17 |
2018-09-04 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело к pd-l1
|
EP4230649A3
(de)
|
2017-04-25 |
2023-10-25 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antikörper und verfahren zur diagnose und behandlung von epstein barr-virusinfektion
|
CA3059468A1
(en)
|
2017-04-27 |
2018-11-01 |
Tesaro, Inc. |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
US11583588B2
(en)
|
2017-05-05 |
2023-02-21 |
Memorial Sloan Kettering Cancer Center |
Modular self assembly disassembly (SADA) technologies
|
JP2020518638A
(ja)
|
2017-05-05 |
2020-06-25 |
アラコス インコーポレイテッド |
アレルギー性眼疾患を処置するための方法および組成物
|
US10646569B2
(en)
|
2017-05-16 |
2020-05-12 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
US11359014B2
(en)
|
2017-05-16 |
2022-06-14 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
WO2018229706A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
US11014978B2
(en)
|
2017-06-22 |
2021-05-25 |
Morphosys Ag |
Canine antibody libraries
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
CA3065954A1
(en)
|
2017-06-27 |
2019-01-03 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identifying and treating resistance to ctla4 antagonists in leukemia
|
WO2019018629A1
(en)
|
2017-07-19 |
2019-01-24 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
|
WO2019018729A1
(en)
|
2017-07-20 |
2019-01-24 |
Dana-Farber Cancer Institute, Inc. |
COMPOSITIONS AND METHODS FOR IDENTIFICATION AND TREATMENT OF NEUROENDOCRINE METASTATIC TUMORS OF INTESTINAL HAIL
|
WO2019020480A1
(en)
|
2017-07-24 |
2019-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
|
US11285149B2
(en)
|
2017-07-28 |
2022-03-29 |
Dana-Farber Cancer Institute, Inc. |
Enhanced immunotherapy of cancer using targeted transcriptional modulators
|
WO2019020807A1
(en)
|
2017-07-28 |
2019-01-31 |
Gene Signal International Sa |
CD9P-1 TARGETING ANTIBODIES AND USES THEREOF
|
EP3601358B1
(de)
|
2017-08-03 |
2023-05-17 |
Alector LLC |
Anti-trem2 antikörper und deren verwendung
|
EP3589658A1
(de)
|
2017-08-03 |
2020-01-08 |
Alector LLC |
Anti-cd33-antikörper und verfahren zur verwendung davon
|
CA3070297A1
(en)
|
2017-08-11 |
2019-02-14 |
Genentech, Inc. |
Anti-cd8 antibodies and uses thereof
|
EP3668898B1
(de)
|
2017-08-14 |
2023-07-05 |
MorphoSys AG |
Humanisierte antikörper für cd3
|
EP3684822A4
(de)
|
2017-09-20 |
2021-06-16 |
The University of British Columbia |
Neue anti-hla-a2-antikörper und verwendungen davon
|
JP7382922B2
(ja)
|
2017-09-20 |
2023-11-17 |
中外製薬株式会社 |
Pd-1系結合アンタゴニストおよびgpc3標的化剤を使用する併用療法のための投与レジメン
|
WO2019057982A1
(en)
|
2017-09-25 |
2019-03-28 |
Morphosys Ag |
TREATMENT OF ATOPIC DERMATITIS
|
EP3688007A1
(de)
|
2017-09-27 |
2020-08-05 |
The University of York |
Biokonjugation von polypeptiden
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
EP3470428A1
(de)
|
2017-10-10 |
2019-04-17 |
Numab Innovation AG |
Anti cd137 antikörper und deren verwendung
|
KR20200063147A
(ko)
|
2017-10-10 |
2020-06-04 |
누맙 세러퓨틱스 아게 |
Pdl1 표적화 항체 및 이의 사용 방법
|
EP3470429A1
(de)
|
2017-10-10 |
2019-04-17 |
Numab Innovation AG |
Auf pdl1 gerichtete antikörper und verfahren zur verwendung davon
|
JP7438939B2
(ja)
|
2017-10-10 |
2024-02-27 |
ヌマブ セラピューティクス アクチェンゲゼルシャフト |
Cd137を標的とする抗体とその利用方法
|
US11753458B2
(en)
|
2017-10-10 |
2023-09-12 |
Alpine Immune Sciences, Inc. |
CTLA-4 variant immunomodulatory proteins and uses thereof
|
CA3185107A1
(en)
|
2017-10-12 |
2019-04-18 |
Immunowake Inc. |
Vegfr-antibody light chain fusion protein
|
WO2019079362A1
(en)
|
2017-10-16 |
2019-04-25 |
Massachusetts Institute Of Technology |
HOST-PATHOGENIC INTERACTION OF MYCOBACTERIUM TUBERCULOSIS
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
MX2020003472A
(es)
*
|
2017-11-01 |
2020-08-03 |
Chugai Pharmaceutical Co Ltd |
Variante e isoforma de anticuerpos con actividad biologica reducida.
|
AU2018372135A1
(en)
|
2017-11-22 |
2020-05-28 |
Novartis Ag |
Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
|
WO2019102456A1
(en)
|
2017-11-27 |
2019-05-31 |
University Of Rijeka Faculty Of Medicine |
Immunotoxins for treating cancer
|
WO2019106578A2
(en)
|
2017-12-01 |
2019-06-06 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
WO2019113506A1
(en)
|
2017-12-07 |
2019-06-13 |
The Broad Institute, Inc. |
Methods and compositions for multiplexing single cell and single nuclei sequencing
|
MX2020006372A
(es)
|
2017-12-19 |
2020-09-03 |
Univ Rockefeller |
Variantes de dominio de fc de igg humana con funcion efectora mejorada.
|
JP7074859B2
(ja)
*
|
2017-12-22 |
2022-05-24 |
エフ.ホフマン-ラ ロシュ アーゲー |
疎水性相互作用クロマトグラフィーによる軽鎖誤対合抗体変種の枯渇の方法
|
KR20200104333A
(ko)
|
2017-12-28 |
2020-09-03 |
난징 레전드 바이오테크 씨오., 엘티디. |
Tigit에 대한 단일-도메인 항체 및 이의 변이체
|
CA3078849A1
(en)
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies and variants thereof against pd-l1
|
WO2019133512A1
(en)
|
2017-12-29 |
2019-07-04 |
Alector Llc |
Anti-tmem106b antibodies and methods of use thereof
|
AU2019205273B2
(en)
|
2018-01-03 |
2024-04-04 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
EP3740507A4
(de)
|
2018-01-15 |
2022-08-24 |
Nanjing Legend Biotech Co., Ltd. |
Einzeldomänenantikörper und varianten davon gegen pd-1
|
WO2019152715A1
(en)
|
2018-01-31 |
2019-08-08 |
Alector Llc |
Anti-ms4a4a antibodies and methods of use thereof
|
WO2019157358A1
(en)
|
2018-02-09 |
2019-08-15 |
Genentech, Inc. |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
BR112020016400A2
(pt)
|
2018-02-14 |
2020-12-15 |
Viela Bio, Inc. |
Anticorpos para o ligante do receptor de tirosina cinase 3 similar ao sarcoma felino de mcdonough (fms) (flt3l) e suas utilizações para o tratamento de doenças autoimunes e inflamatórias
|
JP7391027B2
(ja)
|
2018-02-26 |
2023-12-04 |
ジェネンテック, インコーポレイテッド |
抗tigit及び抗pd-l1アンタゴニスト抗体による治療のための投薬
|
GB201803563D0
(en)
|
2018-03-06 |
2018-04-18 |
Galapagos Nv |
Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
|
US20210253734A1
(en)
|
2018-03-06 |
2021-08-19 |
Imcare Biotech, Llc |
Serine protease inhibitor kazal (spik) compositions and methods
|
RU2020128013A
(ru)
|
2018-03-14 |
2022-04-15 |
Бейцзин Сюаньи Фармасайенсиз Ко., Лтд. |
Антитела против клаудина 18.2
|
KR20200131260A
(ko)
|
2018-03-15 |
2020-11-23 |
비온드 바이오로직스 엘티디 |
가용성 면역 수용체 cd28을 감소시키기 위한 방법 및 조성물
|
MA52091A
(fr)
|
2018-03-21 |
2021-01-27 |
Alx Oncology Inc |
Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
|
CA3093034A1
(en)
|
2018-03-30 |
2019-10-03 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against lag-3 and uses thereof
|
EP3774883A1
(de)
|
2018-04-05 |
2021-02-17 |
Gilead Sciences, Inc. |
Antikörper und fragmente davon, die hepatitis-b-virus-protein x binden
|
TWI811335B
(zh)
|
2018-04-13 |
2023-08-11 |
美商建南德克公司 |
穩定抗cd79b免疫結合物調配物
|
WO2019201904A1
(en)
|
2018-04-16 |
2019-10-24 |
Merck Patent Gmbh |
Viscosity reduction of highly concentrated protein formulations
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
US20210171610A1
(en)
|
2018-05-02 |
2021-06-10 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
MX2020011684A
(es)
|
2018-05-04 |
2020-12-10 |
Merck Patent Gmbh |
Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
|
WO2019213660A2
(en)
|
2018-05-04 |
2019-11-07 |
The Broad Institute, Inc. |
Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
|
CN112088167A
(zh)
|
2018-05-09 |
2020-12-15 |
耶路撒冷希伯来大学伊森姆研究发展有限公司 |
特异性针对人类连接蛋白4的抗体
|
FI3794024T3
(fi)
|
2018-05-14 |
2023-08-10 |
Werewolf Therapeutics Inc |
Aktivoitavia interleukiini-2-polypeptidejä ja niiden käyttömenetelmiä
|
JP2021524756A
(ja)
|
2018-05-14 |
2021-09-16 |
ウェアウルフ セラピューティクス, インコーポレイテッド |
活性化可能なサイトカインポリペプチド及びその使用方法
|
EP3793596A1
(de)
|
2018-05-16 |
2021-03-24 |
MorphoSys AG |
Antikörper gegen glycoprotein vi
|
CA3099917A1
(en)
|
2018-05-24 |
2019-11-28 |
Ares Trading S.A. |
Method for controlling the afucosylation level of a glycoprotein composition
|
US11319373B2
(en)
|
2018-05-25 |
2022-05-03 |
Alector Llc |
Anti-SIRPA antibodies and methods of use thereof
|
CN112165974A
(zh)
|
2018-05-31 |
2021-01-01 |
诺华股份有限公司 |
乙型肝炎抗体
|
KR102480815B1
(ko)
|
2018-05-31 |
2022-12-26 |
글라이코넥스 인코포레이티드 |
바이안테나리 루이스 b 및 루이스 y 항원에 결합하는 치료 항체
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
CN112384531A
(zh)
|
2018-06-01 |
2021-02-19 |
诺华股份有限公司 |
针对bcma的结合分子及其用途
|
JP7382970B2
(ja)
|
2018-06-08 |
2023-11-17 |
アレクトル エルエルシー |
抗Siglec-7抗体及びその使用方法
|
UY38265A
(es)
|
2018-06-20 |
2020-01-31 |
Novartis Ag |
Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
|
TWI819011B
(zh)
|
2018-06-23 |
2023-10-21 |
美商建南德克公司 |
以pd-1 軸結合拮抗劑、鉑劑及拓撲異構酶ii 抑制劑治療肺癌之方法
|
US11203645B2
(en)
|
2018-06-27 |
2021-12-21 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
BR112020026819A2
(pt)
|
2018-06-29 |
2021-04-20 |
Alector Llc |
anticorpos isolados, ácido nucleico, vetor, células hospedeiras, método de produção de um anticorpo, composição farmacêutica, métodos para tratar o câncer e para tratar uma doença e usos de um anticorpo
|
TW202005694A
(zh)
|
2018-07-02 |
2020-02-01 |
美商里珍納龍藥品有限公司 |
自混合物製備多肽之系統及方法
|
WO2020007822A1
(en)
|
2018-07-02 |
2020-01-09 |
Conservatoire National Des Arts Et Metiers (Cnam) |
Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
|
TW202011995A
(zh)
|
2018-07-03 |
2020-04-01 |
比利時商葛萊伯格有限公司 |
高濃度液體抗體配製物
|
TWI809147B
(zh)
|
2018-07-13 |
2023-07-21 |
美商阿列克特有限責任公司 |
抗分揀蛋白抗體及其使用方法
|
JP2021530502A
(ja)
|
2018-07-18 |
2021-11-11 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト、代謝拮抗剤、及びプラチナ製剤で肺がんを治療する方法
|
WO2020023920A1
(en)
|
2018-07-27 |
2020-01-30 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
JP2021533149A
(ja)
|
2018-08-08 |
2021-12-02 |
ジェネンテック, インコーポレイテッド |
タンパク質製剤のためのトリプトファン誘導体及びl−メチオニンの使用
|
SG11202101429YA
(en)
|
2018-08-23 |
2021-03-30 |
Seagen Inc |
Anti-tigit antibodies
|
JP2021534797A
(ja)
|
2018-08-31 |
2021-12-16 |
アレクトル エルエルシー |
抗cd33抗体及びその使用方法
|
EP3849602A1
(de)
|
2018-09-10 |
2021-07-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Kombination eines her2/neu-antikörpers mit häm zur behandlung von krebs
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
EP3857230B1
(de)
|
2018-09-21 |
2023-06-07 |
F. Hoffmann-La Roche AG |
Diagnosemethoden für dreifach-negativen brustkrebs
|
WO2020064971A1
(en)
|
2018-09-26 |
2020-04-02 |
Merck Patent Gmbh |
Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
|
KR20210087027A
(ko)
|
2018-09-27 |
2021-07-09 |
실리오 디벨럽먼트, 인크. |
마스킹된 사이토카인 폴리펩타이드
|
EP3636320A1
(de)
|
2018-10-09 |
2020-04-15 |
Numab Therapeutics AG |
Auf cd137 gerichtete antikörper und verfahren zur verwendung davon
|
AU2019358442A1
(en)
|
2018-10-09 |
2021-03-25 |
Numab Therapeutics AG |
Antibodies targeting CD137 and methods of use thereof
|
CN113329769A
(zh)
|
2018-10-11 |
2021-08-31 |
斯克里普斯研究学院 |
具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物
|
WO2020077236A1
(en)
|
2018-10-12 |
2020-04-16 |
The Broad Institute, Inc. |
Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
|
US20210369705A1
(en)
|
2018-10-15 |
2021-12-02 |
Merck Patent Gmbh |
Combination therapy utilizing dna alkylating agents and atr inhibitors
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
RU2724469C2
(ru)
|
2018-10-31 |
2020-06-23 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с cd20
|
EP3873525A4
(de)
|
2018-11-02 |
2022-07-13 |
Annexon, Inc. |
Zusammensetzungen und verfahren zur behandlung von hirnverletzungen
|
TW202031899A
(zh)
|
2018-11-05 |
2020-09-01 |
美商建南德克公司 |
在原核宿主細胞中產生二鏈蛋白質之方法
|
GB201818477D0
(en)
|
2018-11-13 |
2018-12-26 |
Emstopa Ltd |
Tissue plasminogen activator antibodies and method of use thereof
|
GB201818622D0
(en)
|
2018-11-15 |
2019-01-02 |
Amlo Biosciences Ltd |
Monoclonal antibodies against loricrin
|
GB201818618D0
(en)
|
2018-11-15 |
2019-01-02 |
Amlo Biosciences Ltd |
Monoclonal antibodies against ambra-1
|
US20220008466A1
(en)
|
2018-11-21 |
2022-01-13 |
Indapta Therapeutics, Inc |
Methods for expansion of natural killer (nk) cell subset and related compositions and methods
|
AU2019391791A1
(en)
|
2018-12-03 |
2021-06-03 |
Eirion Therapeutics, Inc. |
Improved delivery of large agents
|
JP2022513708A
(ja)
|
2018-12-05 |
2022-02-09 |
モルフォシス・アーゲー |
多重特異性抗原結合分子
|
MX2021006389A
(es)
|
2018-12-07 |
2021-07-15 |
Jiangsu Hengrui Medicine Co |
Anticuerpo cd3 y uso farmaceutico del mismo.
|
AU2019395841A1
(en)
|
2018-12-14 |
2021-05-20 |
Morphosys Ag |
Antibody formulations
|
WO2020131935A1
(en)
|
2018-12-18 |
2020-06-25 |
Novartis Ag |
Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
|
US20220064311A1
(en)
|
2018-12-18 |
2022-03-03 |
Catapult Therapeutics B.V. |
The use of anti-CCR7 mabs for the prevention or treatment of graft-versus-host disease (GvHD)
|
TW202039554A
(zh)
|
2018-12-19 |
2020-11-01 |
瑞士商諾華公司 |
抗TNF-α抗體
|
WO2020125744A1
(zh)
|
2018-12-21 |
2020-06-25 |
江苏恒瑞医药股份有限公司 |
双特异性蛋白
|
EP3898984A1
(de)
|
2018-12-21 |
2021-10-27 |
Genentech, Inc. |
Verfahren zur herstellung von polypeptiden unter verwendung einer gegen apoptose resistenten zelllinie
|
PE20211296A1
(es)
|
2018-12-21 |
2021-07-20 |
Novartis Ag |
Anticuerpos anti-pmel17 y conjugados de los mismos
|
CA3123050A1
(en)
|
2018-12-26 |
2020-07-02 |
City Of Hope |
Activatable masked anti-ctla4 binding proteins
|
CN113227135A
(zh)
|
2018-12-28 |
2021-08-06 |
斯帕克斯治疗公司 |
用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
AU2020207664A1
(en)
|
2019-01-13 |
2021-07-22 |
University Of Rijeka Faculty Of Medicine |
Antibodies specific to human Nectin-2
|
WO2020150152A1
(en)
|
2019-01-14 |
2020-07-23 |
Genentech, Inc. |
Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
|
EP3689907A1
(de)
|
2019-01-31 |
2020-08-05 |
Numab Therapeutics AG |
Auf il-17a gerichtete antikörper und verfahren zur verwendung davon
|
KR20210122243A
(ko)
|
2019-01-31 |
2021-10-08 |
누맙 세러퓨틱스 아게 |
TNFα 및 IL-17A에 대한 특이성을 가지는 다중 특이적 항체, IL-17A를 표적화하는 항체, 그리고 이의 사용 방법
|
CA3130695A1
(en)
|
2019-02-27 |
2020-09-03 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
|
AU2020231308A1
(en)
|
2019-03-01 |
2021-08-19 |
Allogene Therapeutics, Inc. |
DLL3 targeting chimeric antigen receptors and binding agents
|
CN112969719B
(zh)
|
2019-03-06 |
2022-11-22 |
江苏恒瑞医药股份有限公司 |
双功能融合蛋白及其医药用途
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
WO2020182974A1
(en)
|
2019-03-14 |
2020-09-17 |
Morphosys Ag |
Antibodies targeting c5ar
|
US20220143148A1
(en)
|
2019-03-14 |
2022-05-12 |
The Broad Institute, Inc. |
Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells
|
WO2020183473A1
(en)
|
2019-03-14 |
2020-09-17 |
Biond Biologics Ltd. |
Small shedding blocking agents
|
WO2020187718A1
(en)
|
2019-03-15 |
2020-09-24 |
Morphosys Ag |
Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
|
US20220185875A1
(en)
|
2019-03-18 |
2022-06-16 |
Jiangsu Hengrui Medicine Co., Ltd. |
Bispecific antibody specifically bound to vegf and ang2
|
US20220142948A1
(en)
|
2019-03-18 |
2022-05-12 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
US20220152148A1
(en)
|
2019-03-18 |
2022-05-19 |
The Broad Institute, Inc. |
Modulation of type 2 immunity by targeting clec-2 signaling
|
EP3947446A1
(de)
|
2019-03-25 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Behandlung von tauopathie-erkrankungen durch abzielen auf neue tau-spezies
|
TW202102266A
(zh)
|
2019-04-01 |
2021-01-16 |
美商建南德克公司 |
用於穩定含有蛋白質之配方之組合物及方法
|
CN113711037A
(zh)
|
2019-04-18 |
2021-11-26 |
基因泰克公司 |
抗体效力测定
|
MX2021012506A
(es)
|
2019-04-19 |
2022-01-24 |
Chugai Pharmaceutical Co Ltd |
Receptor quimerico que reconoce un sitio modificado geneticamente en anticuerpo.
|
RU2734432C1
(ru)
|
2019-04-23 |
2020-10-16 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с GITR
|
GB201906297D0
(en)
|
2019-05-03 |
2019-06-19 |
Amlo Biosciences Ltd |
Biomarkers for disease progression in squamous cell carcinoma
|
CN114072424A
(zh)
|
2019-05-03 |
2022-02-18 |
莫佛塞斯公司 |
具有有限数量的nk细胞的患者中的抗cd19疗法
|
GB201906302D0
(en)
|
2019-05-03 |
2019-06-19 |
Amlo Biosciences Ltd |
Methods of determining the margin of a tumour
|
EP3962947A2
(de)
|
2019-05-03 |
2022-03-09 |
F. Hoffmann-La Roche AG |
Verfahren zur behandlung von krebs mit einem anti-pd-l1-antikörper
|
JP2022531911A
(ja)
|
2019-05-07 |
2022-07-12 |
グレイセル・バイオテクノロジーズ(シャンハイ)カンパニー・リミテッド |
Bcmaを標的とする操作された免疫細胞及びその使用
|
CA3139983A1
(en)
|
2019-05-14 |
2020-11-19 |
Eirion Therapeutics, Inc. |
Delaying peak effect and/or extending duration of response
|
CN114450022A
(zh)
|
2019-05-14 |
2022-05-06 |
狼人治疗公司 |
分离部分及其使用方法
|
EP3821250B1
(de)
|
2019-05-16 |
2022-05-04 |
ProciseDx Inc. |
Testverfahren zum nachweis von vcam-1 und alpha-2-makroglobulin in blut
|
JP2022532381A
(ja)
|
2019-05-16 |
2022-07-14 |
プロサイセデクス インコーポレイティド |
Vcam-1及びカルプロテクチンのための分析検出方法
|
KR20220010743A
(ko)
|
2019-05-21 |
2022-01-26 |
노파르티스 아게 |
Bcma에 대한 삼중특이적 결합 분자 및 이의 용도
|
TW202100559A
(zh)
|
2019-05-21 |
2021-01-01 |
瑞士商諾華公司 |
Cd19 結合分子及其用途
|
WO2020236797A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
JP2022534227A
(ja)
|
2019-05-23 |
2022-07-28 |
プロサイセデクス インコーポレイティド |
ヒト血清アルブミン、ビタミンd、c反応性タンパク質、及び抗トランスグルタミナーゼ自己抗体の検出のためのアッセイ方法
|
US20220243178A1
(en)
|
2019-05-31 |
2022-08-04 |
The Broad Institute, Inc. |
Methods for treating metabolic disorders by targeting adcy5
|
AR119264A1
(es)
|
2019-06-05 |
2021-12-09 |
Genentech Inc |
Método para reutilización de cromatografía
|
JP2022535125A
(ja)
|
2019-06-06 |
2022-08-04 |
プロサイセデクス インコーポレイティド |
血中ヘモグロビンA1C(HbA1c)の検出
|
US20200392229A1
(en)
|
2019-06-11 |
2020-12-17 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
UY38747A
(es)
|
2019-06-12 |
2021-01-29 |
Novartis Ag |
Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
|
CA3144324A1
(en)
|
2019-06-24 |
2020-12-30 |
Novartis Ag |
Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
|
WO2020263450A1
(en)
|
2019-06-25 |
2020-12-30 |
Procisedx Inc. |
Detection of anti-tnf alpha drug biologics and anti-drug antibodies
|
MX2021015694A
(es)
|
2019-06-28 |
2022-03-11 |
Genentech Inc |
Composición y métodos para estabilizar formulaciones líquidas de proteínas.
|
CA3145301A1
(en)
|
2019-07-08 |
2021-01-14 |
Imcare Biotech, Llc. |
Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
|
WO2021005232A1
(en)
|
2019-07-11 |
2021-01-14 |
Umc Utrecht Holding B.V. |
Intranasal administration of neutralising antiviral antibodies
|
US20220267452A1
(en)
|
2019-07-12 |
2022-08-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-mutation type fgfr3 antibody and use therefor
|
BR112022000876A2
(pt)
|
2019-07-19 |
2022-04-26 |
Oncoresponse Inc |
Anticorpos imunomoduladores e métodos de uso destes
|
CN114787373A
(zh)
|
2019-07-25 |
2022-07-22 |
免疫苏醒公司 |
测量通过效应子进行的细胞介导的杀伤的方法
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
US11667699B2
(en)
|
2019-07-31 |
2023-06-06 |
Alector Llc |
Anti-MS4A4A antibodies and methods of use thereof
|
GB201911210D0
(en)
|
2019-08-06 |
2019-09-18 |
Amlo Biosciences Ltd |
Clinical management of oropharyngeal squamous cell carcinoma
|
CA3150428A1
(en)
|
2019-08-12 |
2021-02-18 |
Biond Biologics Ltd. |
Antibodies against ilt2 and use thereof
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
MX2022002738A
(es)
|
2019-09-04 |
2022-06-27 |
Genentech Inc |
Agentes de union a cd8 y uso de los mismos.
|
CA3153700A1
(en)
|
2019-09-09 |
2021-03-18 |
Scribe Therapeutics Inc. |
Compositions and methods for use in immunotherapy
|
JP2022547574A
(ja)
|
2019-09-11 |
2022-11-14 |
インケア バイオテック, エルエルシー |
抗セリンプロテアーゼインヒビターkazal(spik)抗体のエピトープ
|
CN114340675A
(zh)
|
2019-09-12 |
2022-04-12 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
BR112022004674A2
(pt)
|
2019-09-17 |
2022-06-07 |
Merck Patent Gmbh |
Ácido canforsulfônico e combinações do mesmo com excipientes catiônicos como agentes de redução de viscosidade em formulações de proteína altamente concentradas
|
JP2022549218A
(ja)
|
2019-09-20 |
2022-11-24 |
ジェネンテック, インコーポレイテッド |
抗トリプターゼ抗体の投薬
|
WO2021062085A1
(en)
|
2019-09-27 |
2021-04-01 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021058729A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
|
JP2022550325A
(ja)
|
2019-09-27 |
2022-12-01 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
抗ミュラー管抑制物質抗体およびその使用
|
GB201914399D0
(en)
|
2019-10-04 |
2019-11-20 |
Univ Newcastle |
Biomarkers for assessing explant organ viability
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
TW202131949A
(zh)
|
2019-10-31 |
2021-09-01 |
德商莫菲西斯公司 |
包含抗CD19抗體及γδ T細胞之抗腫瘤組合療法
|
WO2021084062A1
(en)
|
2019-10-31 |
2021-05-06 |
Morphosys Ag |
Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
|
KR20220095205A
(ko)
|
2019-11-01 |
2022-07-06 |
아레스 트레이딩 에스.아. |
암의 치료를 위한 방사선요법과 PD-1, TGFβ 및 ATM의 조합 억제
|
JP2022554374A
(ja)
|
2019-11-05 |
2022-12-28 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗tigit抗体及びその使用
|
AU2020379201A1
(en)
|
2019-11-05 |
2022-05-26 |
Glaxosmithkline Intellectual Property (No. 4) Ltd. |
Combined inhibition of PD-1, TGFβ and TIGIT for the treatment of cancer
|
JP2022553803A
(ja)
|
2019-11-06 |
2022-12-26 |
ジェネンテック, インコーポレイテッド |
血液がんの処置のための診断方法及び治療方法
|
IL293386A
(en)
|
2019-12-05 |
2022-07-01 |
Alector Llc |
Methods for using anti-trem2 antibodies
|
EP4072682A1
(de)
|
2019-12-09 |
2022-10-19 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antikörper mit spezifität gegen her4 und verwendungen davon
|
EP4073115A1
(de)
|
2019-12-09 |
2022-10-19 |
Novartis AG |
Anti-interleukin-1-beta-antikörper zur behandlung von sichelzellanämie
|
WO2021116277A1
(en)
|
2019-12-10 |
2021-06-17 |
Institut Pasteur |
New antibody blocking human fcgriiia and fcgriiib
|
CA3161206A1
(en)
|
2019-12-12 |
2021-06-17 |
Alector Llc |
Methods of use of anti-cd33 antibodies
|
IL293827A
(en)
|
2019-12-13 |
2022-08-01 |
Alector Llc |
Anti-mertko antibodies and methods of using them
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
MX2022009170A
(es)
|
2020-01-27 |
2022-08-17 |
Genentech Inc |
Procedimientos para el tratamiento del cancer con un anticuerpo antagonista anti-tigit.
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021151974A1
(en)
|
2020-01-28 |
2021-08-05 |
Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis |
Interfering with mrna splicing to enhance response to checkpoint immunotherapies.
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
|
CN115397459A
(zh)
|
2020-01-31 |
2022-11-25 |
基因泰克公司 |
用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法
|
CN113248611A
(zh)
|
2020-02-13 |
2021-08-13 |
湖南华康恒健生物技术有限公司 |
抗bcma抗体、其药物组合物及应用
|
EP4106767A1
(de)
|
2020-02-21 |
2022-12-28 |
Université de Liège |
Erschöpfung der ext1-expression und/oder -aktivität verbessert die zelluläre produktion von biologischen entitäten
|
US20230088052A1
(en)
|
2020-02-21 |
2023-03-23 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition containing anti-il-4r antibody and use thereof
|
CA3167851A1
(en)
|
2020-02-24 |
2021-09-02 |
Francesca CIGNARELLA |
Methods of use of anti-trem2 antibodies
|
US20230142972A1
(en)
|
2020-03-05 |
2023-05-11 |
Umc Utrecht Holding B.V. |
Membrane Ubiquitin ligases to target protein degradation
|
WO2021255280A1
(en)
|
2020-06-18 |
2021-12-23 |
Umc Utrecht Holding B.V. |
Screening method for effective target - e3 ligase combinations
|
WO2021183849A1
(en)
|
2020-03-13 |
2021-09-16 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
US20230128499A1
(en)
|
2020-03-27 |
2023-04-27 |
Novartis Ag |
Bispecific combination therapy for treating proliferative diseases and autoimmune diseases
|
WO2021202590A1
(en)
|
2020-03-31 |
2021-10-07 |
Alector Llc |
Anti-mertk antibodies and methods of use thereof
|
EP4126953A2
(de)
|
2020-04-03 |
2023-02-08 |
Alector LLC |
Verfahren zur verwendung von anti-trem2-antikörpern
|
US20230183342A1
(en)
|
2020-04-06 |
2023-06-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
|
JP2023521785A
(ja)
|
2020-04-09 |
2023-05-25 |
テクニッシェ ウニベルシタット ミュンヘン |
肺線維症の治療のためのマクロファージへのmiR-21阻害剤の標的送達
|
WO2021209458A1
(en)
|
2020-04-14 |
2021-10-21 |
Ares Trading S.A. |
Combination treatment of cancer
|
US20230149360A1
(en)
|
2020-04-21 |
2023-05-18 |
Université Catholique de Louvain |
Alpha-2 adrenergic receptor agonists for the prevention and/or the treatment of spleen disorders
|
WO2021214129A1
(en)
|
2020-04-21 |
2021-10-28 |
Université Catholique de Louvain |
Alpha-2 adrenergic receptor agonists for the treatment of cancer
|
US20230159939A1
(en)
|
2020-04-22 |
2023-05-25 |
Fabmid |
Methods for circularizing linear double stranded nucleic acids
|
CN116368221A
(zh)
|
2020-04-22 |
2023-06-30 |
因达普塔治疗公司 |
自然杀伤(nk)细胞组合物及其生成方法
|
CA3172880A1
(en)
|
2020-04-27 |
2021-11-04 |
Sotirios Tsimikas |
Isoform-independent antibodies to lipoprotein(a)
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
WO2021222533A1
(en)
|
2020-04-30 |
2021-11-04 |
Procisedx Inc. |
Methods of detecting antibodies to sars-cov-2
|
JP2023525033A
(ja)
|
2020-05-08 |
2023-06-14 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Aprilおよびbaff阻害免疫調節タンパク質、ならびにその使用方法
|
CA3180683A1
(en)
|
2020-05-12 |
2021-11-18 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
GB202007312D0
(en)
|
2020-05-18 |
2020-07-01 |
Synthetic Vac Ltd |
Mimotope peptides of the spike protein from the sars-cov-2 virus
|
US20230183376A1
(en)
|
2020-05-22 |
2023-06-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody for neutralizing substance having coagulation factor viii (f.viii) function-substituting activity
|
GB202008651D0
(en)
|
2020-06-09 |
2020-07-22 |
Univ Newcastle |
Method of identifying complement modulators
|
CN115916182A
(zh)
|
2020-06-16 |
2023-04-04 |
基因泰克公司 |
用于治疗三阴性乳腺癌的方法和组合物
|
US20210395366A1
(en)
|
2020-06-18 |
2021-12-23 |
Genentech, Inc. |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
CA3181827A1
(en)
|
2020-06-22 |
2021-12-30 |
Morphosys Ag |
Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirp?-cd47 innate immune checkpoint
|
EP4180456A4
(de)
|
2020-07-09 |
2024-04-03 |
Beijing Kawin Tech Share Holding Co Ltd |
Antikörper mit bindung an hepatitis-b-virus-oberflächenantigen und anwendung des antikörpers
|
MX2023000547A
(es)
|
2020-07-16 |
2023-02-13 |
Novartis Ag |
Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas.
|
MX2023000903A
(es)
|
2020-07-23 |
2023-04-20 |
Univ Erasmus Med Ct Rotterdam |
Proteinas s100 como nuevos objetivos terapeuticos en neoplasias mieloproliferativas.
|
FR3112939B1
(fr)
|
2020-07-31 |
2024-01-05 |
Univ Montpellier |
Produit universel de thérapie cellulaire et son utilisation
|
WO2022031749A1
(en)
|
2020-08-03 |
2022-02-10 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
WO2022035793A1
(en)
|
2020-08-10 |
2022-02-17 |
Precision Biosciences, Inc. |
Antibodies and fragments specific for b-cell maturation antigen and uses thereof
|
TW202221035A
(zh)
|
2020-08-12 |
2022-06-01 |
以色列商拜恩德生物製品有限公司 |
抗ilt2抗體及其用途
|
WO2022044010A1
(en)
|
2020-08-26 |
2022-03-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
|
CN114106173A
(zh)
|
2020-08-26 |
2022-03-01 |
上海泰槿生物技术有限公司 |
抗ox40抗体、其药物组合物及应用
|
AU2021339953A1
(en)
|
2020-09-11 |
2023-05-18 |
Medimmune Limited |
Therapeutic b7-h4 binding molecules
|
FR3114160A1
(fr)
|
2020-09-11 |
2022-03-18 |
Dyameo |
Rapporteur fluorescent et son utilisation pour la détection de molécules cibles
|
AU2021342349A1
(en)
|
2020-09-12 |
2023-05-25 |
Medimmune Limited |
A scoring method for an anti-b7h4 antibody-drug conjugate therapy
|
KR20230073196A
(ko)
|
2020-09-21 |
2023-05-25 |
제넨테크, 인크. |
다중특이성 항체의 정제
|
EP4217391A1
(de)
|
2020-09-24 |
2023-08-02 |
MorphoSys AG |
Neue humane antikörper, die an humanes cd3-epsilon binden
|
AU2021347978A1
(en)
|
2020-09-24 |
2023-03-16 |
Genentech, Inc. |
Polysorbate mixtures having modified fatty acid ester distribution
|
US20240025992A1
(en)
|
2020-10-22 |
2024-01-25 |
Janssen Biotech, Inc. |
Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
CA3196557A1
(en)
|
2020-11-02 |
2022-05-05 |
Ada SALA-HOJMAN |
Combination treatment of cancer
|
WO2022090529A1
(en)
|
2020-11-02 |
2022-05-05 |
Ares Trading S.A. |
Combination treatment of cancer
|
IL302639A
(en)
|
2020-11-04 |
2023-07-01 |
Myeloid Therapeutics Inc |
Engineered chimeric fusion protein compositions and methods of using them
|
WO2022097090A1
(en)
|
2020-11-05 |
2022-05-12 |
Novartis Ag |
Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
|
CN116390933A
(zh)
|
2020-11-06 |
2023-07-04 |
诺华股份有限公司 |
治疗b细胞恶性肿瘤的抗cd19剂和b细胞靶向剂组合疗法
|
WO2022097065A2
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
TW202233248A
(zh)
|
2020-11-08 |
2022-09-01 |
美商西健公司 |
組合療法
|
JP2023549925A
(ja)
|
2020-11-24 |
2023-11-29 |
ノバルティス アーゲー |
抗cd48抗体、抗体薬物コンジュゲート及びその使用
|
US20240101681A1
(en)
|
2020-12-02 |
2024-03-28 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
CA3204063A1
(en)
|
2020-12-04 |
2022-06-09 |
Morphosys Ag |
Anti-cd19 combination therapy
|
CN116802211A
(zh)
|
2020-12-07 |
2023-09-22 |
Ucb生物制药有限责任公司 |
针对白介素-22的抗体
|
US20240067758A1
(en)
|
2020-12-07 |
2024-02-29 |
UCB Biopharma SRL |
Multi-specific antibodies and antibody combinations
|
WO2022125710A1
(en)
|
2020-12-09 |
2022-06-16 |
GHP Solutions, LLC |
Methods of detecting papp-a and related methods for gestational age assessment
|
US20240052042A1
(en)
|
2020-12-14 |
2024-02-15 |
Novartis Ag |
Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
JP2024503724A
(ja)
|
2021-01-20 |
2024-01-26 |
オンコレスポンス,インク. |
免疫調節抗体およびその使用
|
CA3206413A1
(en)
|
2021-02-11 |
2022-08-18 |
Pinchas TSUKERMAN |
Antibodies against cd112r and uses thereof
|
TW202317612A
(zh)
|
2021-03-01 |
2023-05-01 |
美商艾希利歐發展股份有限公司 |
用於治療癌症的ctla4及pd1/pdl1抗體之組合
|
TW202246324A
(zh)
|
2021-03-01 |
2022-12-01 |
美商艾希利歐發展股份有限公司 |
用於治療癌症的經掩蔽之ctla4及pd1/pdl1抗體之組合
|
JP2024508157A
(ja)
|
2021-03-04 |
2024-02-22 |
センター ナショナル デ ラ レシェルシェ サイエンティフィーク |
炎症、線維症及び肺疾患を治療するためのペリオスチン抗体の使用
|
AU2022232951A1
(en)
|
2021-03-10 |
2023-10-19 |
Immunowake Inc. |
Immunomodulatory molecules and uses thereof
|
WO2022198192A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
EP4308606A1
(de)
|
2021-03-18 |
2024-01-24 |
Alector LLC |
Anti-tmem106b-antikörper und verfahren zu ihrer verwendung
|
AU2022236492A1
(en)
|
2021-03-18 |
2023-10-26 |
Medimmune Limited |
Therapeutic binding molecule that binds to ccr9
|
EP4314063A1
(de)
|
2021-03-23 |
2024-02-07 |
Alector LLC |
Anti-tmem106b-antikörper zur behandlung und prävention von coronavirusinfektionen
|
IL307168A
(en)
|
2021-03-26 |
2023-11-01 |
Janssen Biotech Inc |
Humanized antibodies against paired helical strands of TAU protein and their uses
|
CN117730097A
(zh)
|
2021-04-09 |
2024-03-19 |
思进公司 |
以抗tigit抗体治疗癌症的方法
|
EP4323526A1
(de)
|
2021-04-16 |
2024-02-21 |
Novartis AG |
Antikörper-wirkstoff-konjugate und verfahren zur herstellung davon
|
EP4326288A1
(de)
|
2021-04-21 |
2024-02-28 |
Indapta Therapeutics, Inc. |
Verfahren zur behandlung und dosierung von natürlichen killerzellzusammensetzungen
|
JP2024516305A
(ja)
|
2021-05-03 |
2024-04-12 |
ユーシービー バイオファルマ エスアールエル |
抗体
|
CA3218697A1
(en)
|
2021-05-03 |
2022-11-10 |
Merck Patent Gmbh |
Her2 targeting fc antigen binding fragment-drug conjugates
|
EP4333869A1
(de)
|
2021-05-07 |
2024-03-13 |
Alpine Immune Sciences, Inc. |
Verfahren zur dosierung und behandlung mit einem taci-fc-fusionsimmunmodulatorischen protein
|
EP4337689A1
(de)
|
2021-05-12 |
2024-03-20 |
Applied Biomedical Science Institute |
Bindungspolypeptide gegen sars cov-2 und verwendungen davon
|
WO2022242710A1
(zh)
|
2021-05-19 |
2022-11-24 |
上海诗健生物科技有限公司 |
一种特异性识别baff-r的嵌合抗原受体分子及其应用
|
AU2022280341A1
(en)
|
2021-05-25 |
2024-01-04 |
Merck Patent Gmbh |
Egfr targeting fc antigen binding fragment-drug conjugates
|
CN117858723A
(zh)
|
2021-06-07 |
2024-04-09 |
阿雷斯贸易股份有限公司 |
癌症的联合治疗
|
WO2022266221A1
(en)
|
2021-06-16 |
2022-12-22 |
Alector Llc |
Monovalent anti-mertk antibodies and methods of use thereof
|
WO2022266223A1
(en)
|
2021-06-16 |
2022-12-22 |
Alector Llc |
Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
|
WO2022263057A1
(en)
|
2021-06-18 |
2022-12-22 |
Advancecor Gmbh |
Use of a pharmaceutical composition
|
WO2023278811A1
(en)
|
2021-07-01 |
2023-01-05 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
CA3227537A1
(en)
|
2021-07-27 |
2023-02-02 |
Morphosys Ag |
Combinations of antigen binding molecules
|
WO2023006919A1
(en)
|
2021-07-29 |
2023-02-02 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
HUMANIZED ANTI-HUMAN βIG-H3 PROTEIN AND USES THEREOF
|
WO2023019239A1
(en)
|
2021-08-13 |
2023-02-16 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
US20230144608A1
(en)
|
2021-09-14 |
2023-05-11 |
Xilio Development, Inc. |
Cleavable linkers
|
WO2023064872A1
(en)
|
2021-10-14 |
2023-04-20 |
Precision Biosciences, Inc. |
Combinations of anti-bcma car t cells and gamma secretase inhibitors
|
WO2023064947A1
(en)
|
2021-10-15 |
2023-04-20 |
Regenxbio Inc. |
Antibodies and methods of using thereof
|
WO2023069919A1
(en)
|
2021-10-19 |
2023-04-27 |
Alector Llc |
Anti-cd300lb antibodies and methods of use thereof
|
WO2023072958A1
(en)
|
2021-10-25 |
2023-05-04 |
Fabmid |
Methods for circularizing linear double stranded nucleic acids and the products thereof
|
TW202325345A
(zh)
|
2021-10-27 |
2023-07-01 |
美商建南德克公司 |
約束性複合劑之合成
|
WO2023072916A1
(en)
|
2021-10-27 |
2023-05-04 |
Granite Bio Ag |
Antibodies targeting ccr2
|
WO2023081898A1
(en)
|
2021-11-08 |
2023-05-11 |
Alector Llc |
Soluble cd33 as a biomarker for anti-cd33 efficacy
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
WO2023105528A1
(en)
|
2021-12-12 |
2023-06-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to ceacam1
|
WO2023117987A1
(en)
|
2021-12-21 |
2023-06-29 |
Universität Zürich |
Adenoviral vectors
|
WO2023122665A1
(en)
|
2021-12-22 |
2023-06-29 |
Genentech, Inc. |
Clinical formulations of anti-tigit antibodies
|
WO2023122796A1
(en)
|
2021-12-23 |
2023-06-29 |
The Broad Institute, Inc. |
Parallel antibody engineering compositions and methods
|
WO2023148707A1
(en)
|
2022-02-07 |
2023-08-10 |
Yeda Research And Development Co. Ltd. |
Humanized anti quiescin suefhydrye oxidase 1 (qsox1) antibodies and uses thereof
|
TW202348252A
(zh)
|
2022-02-16 |
2023-12-16 |
英商梅迪繆思有限公司 |
用治療性結合分子治療癌症的組合療法
|
WO2023156625A1
(en)
|
2022-02-18 |
2023-08-24 |
Adivo Gmbh |
Feline antibody library
|
WO2023164516A1
(en)
|
2022-02-23 |
2023-08-31 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
GB202202569D0
(en)
|
2022-02-24 |
2022-04-13 |
Amlo Biosciences Ltd |
Biomarkers for disease progression and/or recurrence in squamous cell carcinoma
|
WO2023164286A1
(en)
|
2022-02-28 |
2023-08-31 |
Xilio Development, Inc. |
Engineered cd122 compositions and methods thereof
|
WO2023164288A2
(en)
|
2022-02-28 |
2023-08-31 |
Xilio Development, Inc. |
Targeted cytokines and methods of use thereof
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
TW202345899A
(zh)
|
2022-03-11 |
2023-12-01 |
比利時商健生藥品公司 |
多特異性抗體及其用途(三)
|
WO2023170296A1
(en)
|
2022-03-11 |
2023-09-14 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Nucleic acid system to specifically reprogram b and t cells and uses thereof
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
WO2023170290A1
(en)
|
2022-03-11 |
2023-09-14 |
Janssen Pharmaceutica Nv |
Multispecific antibodies and uses thereof
|
WO2023170291A1
(en)
|
2022-03-11 |
2023-09-14 |
Janssen Pharmaceutica Nv |
Multispecific antibodies and uses thereof
|
WO2023175171A1
(en)
|
2022-03-18 |
2023-09-21 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Bk polyomavirus antibodies and uses thereof
|
WO2023180346A1
(en)
|
2022-03-22 |
2023-09-28 |
Morphosys Ag |
Deimmunized antibodies specific for cd3
|
WO2023180527A1
(en)
|
2022-03-25 |
2023-09-28 |
Universität Zürich |
Adenoviral mediated targeting of activated immune cells
|
WO2023187657A1
(en)
|
2022-03-30 |
2023-10-05 |
Novartis Ag |
Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
|
US20230364020A1
(en)
|
2022-04-01 |
2023-11-16 |
Genentech, Inc. |
Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
|
TW202340259A
(zh)
|
2022-04-14 |
2023-10-16 |
瑞士商諾華公司 |
抗cd19藥劑之劑量方案及其用途
|
WO2023209716A1
(en)
|
2022-04-25 |
2023-11-02 |
Biond Biologics Ltd. |
Anti-ilt3 antibodies and use thereof
|
EP4269432A1
(de)
|
2022-04-26 |
2023-11-01 |
Universite de Rouen Normandie |
Herstellung von therapeutischen antikörpern durch die mikroalge phaeodactylum tricornutum
|
TW202400658A
(zh)
|
2022-04-26 |
2024-01-01 |
瑞士商諾華公司 |
靶向il—13和il—18的多特異性抗體
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024008910A1
(en)
|
2022-07-07 |
2024-01-11 |
Cimeio Therapeutics Ag |
Antibodies targeting cd117
|
WO2024016003A2
(en)
|
2022-07-14 |
2024-01-18 |
The Broad Institute, Inc. |
Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor
|
WO2024015960A1
(en)
|
2022-07-15 |
2024-01-18 |
Xilio Development, Inc. |
Engineered cleavable fc domain as carriers and methods of use thereof
|
WO2024026447A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Anti-gpnmb antibodies and methods of use thereof
|
US20240092859A1
(en)
|
2022-08-18 |
2024-03-21 |
Immunocore Ltd |
T cell receptors and fusion proteins thereof
|
WO2024047114A1
(en)
|
2022-08-31 |
2024-03-07 |
Universität Zürich |
Adenoviral-based in situ delivery of bispecific t cell engagers
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024056668A1
(en)
|
2022-09-12 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
New anti-itgb8 antibodies and its uses thereof
|
WO2024077018A2
(en)
|
2022-10-04 |
2024-04-11 |
Alpine Immune Sciences, Inc. |
Methods and uses of taci-fc fusion immunomodulatory protein
|
WO2024074649A1
(en)
|
2022-10-05 |
2024-04-11 |
Alcea Therapeutics, Inc. |
Notch4 antibodies, compositions, and methods for treating airway inflammation
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
WO2024074706A1
(en)
|
2022-10-07 |
2024-04-11 |
Universität Zürich |
Paracrine adenoviral delivery of biomolecules
|